<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="barth" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">barth</book-part-id>
      <title-group>
        <title>Barth Syndrome</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ferreira</surname>
            <given-names>Carlos</given-names>
          </name>
          <degrees>MD</degrees>
          <aff>Post-doctoral fellow, Medical Genetics Branch<break/>National Human Genome Research Institute<break/>National Institutes of Health<break/>Bethesda, Maryland</aff>
          <email>ferreiracr@mail.nih.gov</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Thompson</surname>
            <given-names>Reid</given-names>
          </name>
          <degrees>MD</degrees>
          <aff>Assistant Professor, Pediatric Cardiology<break/>Johns Hopkins University<break/>Baltimore, Maryland</aff>
          <email>thompson@jhmi.edu</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Vernon</surname>
            <given-names>Hilary</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <aff>Assistant Professor, McKusick-Nathans Institute of Genetic Medicine<break/>Johns Hopkins University<break/>Baltimore, Maryland</aff>
          <email>hvernon1@jhmi.edu</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date date-type="created">
          <day>9</day>
          <month>10</month>
          <year>2014</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="bbs" document-type="chapter">Bardet-Biedl Syndrome</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="bws" document-type="chapter">Beckwith-Wiedemann Syndrome</related-object>
      <abstract id="barth.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Barth syndrome is characterized in affected males by cardiomyopathy, neutropenia, skeletal myopathy, prepubertal growth delay, and distinctive facial gestalt (most evident in infancy); not all features may be present in a given patient. Cardiomyopathy, which is almost always present before age five years, is typically dilated cardiomyopathy with or without endocardial fibroelastosis (EFE) or left ventricular noncompaction (LVNC); rarely it is hypertrophic cardiomyopathy (HCM). Heart failure is a significant cause of morbidity and mortality; risk of arrhythmia and sudden death is increased. Neutropenia is most often associated with mouth ulcers, pneumonia, and sepsis. The non-progressive myopathy predominantly affects the proximal muscles, and results in early motor delays. Prepubertal growth delay is followed by a post-pubertal growth spurt with remarkable &#x0201c;catch-up&#x0201d; growth. Heterozygous females who have a normal karyotype are asymptomatic and have normal biochemical studies.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of Barth syndrome is suggested by typical clinical findings, a five- to 20-fold increase in urinary 3-methylglutaconic acid (3-MGC), and moderately increased urinary 3-methylglutaric acid and 2-ethylhydracrylic acid. The diagnosis is established in a male proband with either an increased monolysocardiolipin:cardiolipin ratio (if available) or detection of a <italic toggle="yes">TAZ</italic> pathogenic variant on molecular genetic testing.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Standard heart failure medications are used for in-patient and outpatient care. Daily use of aspirin to help prevent clot formation and, thus reduce the risk of stroke in males with severe cardiac dysfunction and/or marked LVNC should be considered. The potential role of prophylactic antiarrhythmic medication or an implantable cardiac defibrillator has not been clarified. Cardiac transplantation has been successful when heart failure is severe and intractable. The treatment of neutropenia can include regular administration of granulocyte colony stimulating factor (G-CSF), administration of G-CSF during times of high risk only (e.g., surgery or infection), prophylactic antibiotics, and other preventive treatment strategies. Uncooked cornstarch given prior to bedtime has been recommended as a means of avoiding muscle protein loss overnight. Excessive fatigue and the specific cognitive profile warrant educational support during the early school-age years.</p>
          <p><italic toggle="yes">Prevention of secondary complications:</italic> Granulocyte-colony stimulating factor (G-CSF) or antibiotic prophylaxis to prevent recurrent infections can be considered; limiting episodes of necessary fasting (e.g., prior to surgery) and simultaneously providing intravenous glucose; monitoring serum potassium levels for hypokalemia during episodes of diarrhea and for hyperkalemia during administration of intravenous fluids containing potassium.</p>
          <p><italic toggle="yes">Surveillance:</italic> Monitor height and weight on a regular basis with consideration to Barth syndrome-specific growth patterns; consider at least annual standardized cardiac evaluation including EKG, ECG, and Holter monitoring; assess for a potentially serious arrhythmia in the presence of symptoms (e.g., palpitations, syncope), abnormal screening tests, or a family history of sudden death.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> The use of rectal thermometers in those with neutropenia; the use of succinylcholine, as non-depolarizing neuromuscular blockers could have a prolonged effect.</p>
          <p><italic toggle="yes">Evaluation of relatives at risk:</italic> It is appropriate to evaluate the older and younger brothers of a proband in order to identify as early as possible those who would benefit from initiation of treatment and preventive measures.</p>
          <p><italic toggle="yes">Pregnancy management:</italic> Because of the increased risk for prenatal complications (e.g., intrauterine growth restriction, oligohydramnios, intrauterine ventricular dysfunction, hydrops fetalis), it seems prudent to recommend that pregnancies of male fetuses known to have Barth syndrome be managed by a high-risk maternal fetal obstetrician.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>Barth syndrome is inherited in an X-linked manner. If a mother has a <italic toggle="yes">TAZ</italic> pathogenic variant, the chance of transmitting it in each pregnancy is 50%. Males who inherit the <italic toggle="yes">TAZ</italic> pathogenic variant will be affected; females who inherit the <italic toggle="yes">TAZ</italic> pathogenic variant will be carriers and will not be affected. Affected males pass the <italic toggle="yes">TAZ</italic> pathogenic variant to all of their daughters and none of their sons. Carrier testing for at-risk female relatives and prenatal testing for pregnancies at increased risk are possible if the <italic toggle="yes">TAZ</italic> pathogenic variant has been identified in an affected family member.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="barth.Diagnosis">
        <title>Diagnosis</title>
        <sec id="barth.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p>Diagnosis of Barth syndrome should be suspected in male children with a combination of any of the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>At least one of the following cardiac findings:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Dilated cardiomyopathy &#x000b1; endocardial fibroelastosis (EFE): ventricular chamber enlargement and contractile dysfunction in the setting of normal left ventricular wall thickness, with or without diffuse thickening of the ventricular endocardium</p>
                </list-item>
                <list-item>
                  <p>Left ventricular noncompaction (LVNC): noncompacted left ventricular myocardium with prominent trabeculations and deep intertrabecular recesses that communicate with the ventricular cavity</p>
                </list-item>
                <list-item>
                  <p>Hypertrophic cardiomyopathy (HCM) (much less common): characterized by increased ventricular wall thickness</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Neutropenia</p>
              <list list-type="bullet">
                <list-item>
                  <p>Defined as:</p>
                  <list list-type="bullet">
                    <list-item>
                      <p>Mild neutropenia. Absolute neutrophil count (ANC) between 1000 and 1500 cells/&#x000b5;L;</p>
                    </list-item>
                    <list-item>
                      <p>Moderate neutropenia. ANC between 500 and 1000 cells/&#x000b5;L;</p>
                    </list-item>
                    <list-item>
                      <p>Severe neutropenia. ANC&#x0003c;500 cells/&#x000b5;L.</p>
                    </list-item>
                  </list>
                </list-item>
                <list-item>
                  <p>In a study of 83 males with Barth syndrome, the median ANC was 1100 cells/&#x000b5;L (range: 140-5400 cells/&#x000b5;L) [<xref ref-type="bibr" rid="barth.REF.dale.2013">Dale et al 2013</xref>]. These findings are similar to those of a French cohort in which the median ANC was 1300 cells/&#x000b5;L (range: 0-6400 cells/&#x000b5;L) [<xref ref-type="bibr" rid="barth.REF.rigaud.2013.70">Rigaud et al 2013</xref>]. In both studies, the ANC fluctuated, but without detectable periodicity.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Skeletal myopathy or hypotonia</p>
            </list-item>
            <list-item>
              <p>Prepubertal growth delay</p>
            </list-item>
            <list-item>
              <p>Typical dysmorphic findings in infants and toddlers including round face, full cheeks, prominent pointed chin, large ears, and deep-set eyes</p>
            </list-item>
            <list-item>
              <p>A family history consistent with X-linked inheritance, including recurrent pregnancy loss involving male fetuses [<xref ref-type="bibr" rid="barth.REF.steward.2010.970">Steward et al 2010</xref>]</p>
            </list-item>
          </list>
        </sec>
        <sec id="barth.Preliminary_Testing">
          <title>Preliminary Testing</title>
          <p><bold>Urine organic acids.</bold> 3-methylglutaconic acid (3-MGC) is typically increased five- to 20-fold [<xref ref-type="bibr" rid="barth.REF.clarke.2013.23">Clarke et al 2013</xref>] with an average value of 44.6 &#x000b1; 25 (SD) &#x003bc;g/mg Cr (<xref ref-type="table" rid="barth.T.urine_and_plasma_organic_acid_le">Table 1</xref>).</p>
          <p>Note: Urinary 3-MGC levels can be normal on single sample testing [<xref ref-type="bibr" rid="barth.REF.gedeon.1995.383">Gedeon et al 1995</xref>, <xref ref-type="bibr" rid="barth.REF.bleyl.1997.257">Bleyl et al 1997</xref>, <xref ref-type="bibr" rid="barth.REF.jarvis.2001.175">Jarvis et al 2001</xref>, <xref ref-type="bibr" rid="barth.REF.schmidt.2004.419">Schmidt et al 2004</xref>, <xref ref-type="bibr" rid="barth.REF.brady.2006.462">Brady et al 2006</xref>, <xref ref-type="bibr" rid="barth.REF.donati.2006.684">Donati et al 2006</xref>, <xref ref-type="bibr" rid="barth.REF.takeda.2011.1481">Takeda et al 2011</xref>].</p>
          <list list-type="bullet">
            <list-item>
              <p>In one study all 28 patients ranging in age from ten months to 30 years had elevated urine 3-MGC levels [<xref ref-type="bibr" rid="barth.REF.vernon.2014.143">Vernon et al 2014</xref>].</p>
            </list-item>
            <list-item>
              <p>In contrast, only eight of 16 individuals in a French cohort had elevated 3-MGC levels [<xref ref-type="bibr" rid="barth.REF.rigaud.2013.70">Rigaud et al 2013</xref>].</p>
            </list-item>
          </list>
          <p>3-methylglutaric acid and 2-ethylhydracrylic acid can be moderately elevated. [<xref ref-type="bibr" rid="barth.REF.kelley.1991.738">Kelley et al 1991</xref>].</p>
          <p><bold>Plasma 3 methylglutaconic acid (3-MGC).</bold> In a single study, 28 of 28 affected individuals ranging in age from ten months to 30 years had elevated plasma 3-MGC levels, with an average of 1088 nmol/L &#x000b1; 435 (range: 393-2326 nmol/L) [<xref ref-type="bibr" rid="barth.REF.vernon.2014.143">Vernon et al 2014</xref>] (see <xref ref-type="table" rid="barth.T.urine_and_plasma_organic_acid_le">Table 1</xref>).</p>
          <table-wrap id="barth.T.urine_and_plasma_organic_acid_le" orientation="portrait" position="anchor">
            <label>Table 1. </label>
            <caption>
              <p>Urine and Plasma Organic Acid Levels in Barth Syndrome</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_barth.T.urine_and_plasma_organic_acid_le_1_1_1_1" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_barth.T.urine_and_plasma_organic_acid_le_1_1_1_1">Organic Acid</th>
                  <th id="hd_h_barth.T.urine_and_plasma_organic_acid_le_1_1_1_2" valign="middle" colspan="2" align="left" scope="colgroup" rowspan="1">In Urine (&#x003bc;g/mg Cr)</th>
                  <th id="hd_h_barth.T.urine_and_plasma_organic_acid_le_1_1_1_3" valign="middle" colspan="2" align="left" scope="colgroup" rowspan="1">In Plasma (nmol/L)</th>
                </tr>
                <tr>
                  <th headers="hd_h_barth.T.urine_and_plasma_organic_acid_le_1_1_1_2" id="hd_h_barth.T.urine_and_plasma_organic_acid_le_1_1_2_1" valign="middle" colspan="1" align="left" scope="colgroup" rowspan="1">Barth Syndrome</th>
                  <th headers="hd_h_barth.T.urine_and_plasma_organic_acid_le_1_1_1_2" id="hd_h_barth.T.urine_and_plasma_organic_acid_le_1_1_2_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Control</th>
                  <th headers="hd_h_barth.T.urine_and_plasma_organic_acid_le_1_1_1_3" id="hd_h_barth.T.urine_and_plasma_organic_acid_le_1_1_2_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Barth Syndrome</th>
                  <th headers="hd_h_barth.T.urine_and_plasma_organic_acid_le_1_1_1_3" id="hd_h_barth.T.urine_and_plasma_organic_acid_le_1_1_2_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Control</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_barth.T.urine_and_plasma_organic_acid_le_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">3-methylglutaconic acid</td>
                  <td headers="hd_h_barth.T.urine_and_plasma_organic_acid_le_1_1_1_2 hd_h_barth.T.urine_and_plasma_organic_acid_le_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">Avg: 44.6&#x000b1;25 (SD)&#x000a0;<sup>1</sup><break/>&#x02191;5- to 20-fold&#x000a0;<sup>2</sup></td>
                  <td headers="hd_h_barth.T.urine_and_plasma_organic_acid_le_1_1_1_2 hd_h_barth.T.urine_and_plasma_organic_acid_le_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">0-2y:6.6&#x000b1;2.4<break/>2-12y:5.3&#x000b1;2.4<break/>Adult: 3.7&#x000b1;1.8</td>
                  <td headers="hd_h_barth.T.urine_and_plasma_organic_acid_le_1_1_1_3 hd_h_barth.T.urine_and_plasma_organic_acid_le_1_1_2_3" valign="middle" align="left" rowspan="1" colspan="1">1088&#x000b1;435<break/>(range: 393-2326)&#x000a0;<sup>1</sup></td>
                  <td headers="hd_h_barth.T.urine_and_plasma_organic_acid_le_1_1_1_3 hd_h_barth.T.urine_and_plasma_organic_acid_le_1_1_2_4" valign="middle" align="left" rowspan="1" colspan="1">162&#x000b1;68</td>
                </tr>
                <tr>
                  <td headers="hd_h_barth.T.urine_and_plasma_organic_acid_le_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">3-methylglutaric acid</td>
                  <td headers="hd_h_barth.T.urine_and_plasma_organic_acid_le_1_1_1_2 hd_h_barth.T.urine_and_plasma_organic_acid_le_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">Moderately&#x02191;&#x000a0;<sup>3</sup></td>
                  <td headers="hd_h_barth.T.urine_and_plasma_organic_acid_le_1_1_1_2 hd_h_barth.T.urine_and_plasma_organic_acid_le_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_barth.T.urine_and_plasma_organic_acid_le_1_1_1_3 hd_h_barth.T.urine_and_plasma_organic_acid_le_1_1_2_3" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_barth.T.urine_and_plasma_organic_acid_le_1_1_1_3 hd_h_barth.T.urine_and_plasma_organic_acid_le_1_1_2_4" valign="middle" align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_barth.T.urine_and_plasma_organic_acid_le_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">2-ethylhydracrylic acid</td>
                  <td headers="hd_h_barth.T.urine_and_plasma_organic_acid_le_1_1_1_2 hd_h_barth.T.urine_and_plasma_organic_acid_le_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">Moderately&#x02191;&#x000a0;<sup>3</sup><break/>6.7&#x000b1;25&#x000a0;<sup>1</sup></td>
                  <td headers="hd_h_barth.T.urine_and_plasma_organic_acid_le_1_1_1_2 hd_h_barth.T.urine_and_plasma_organic_acid_le_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Trace</td>
                  <td headers="hd_h_barth.T.urine_and_plasma_organic_acid_le_1_1_1_3 hd_h_barth.T.urine_and_plasma_organic_acid_le_1_1_2_3" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_barth.T.urine_and_plasma_organic_acid_le_1_1_1_3 hd_h_barth.T.urine_and_plasma_organic_acid_le_1_1_2_4" valign="middle" align="left" rowspan="1" colspan="1"/>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="barth.TF.1.1">
                <label>1. </label>
                <p>
                  <xref ref-type="bibr" rid="barth.REF.vernon.2013">Vernon et al [2013]</xref>
                </p>
              </fn>
              <fn id="barth.TF.1.2">
                <label>2. </label>
                <p>
                  <xref ref-type="bibr" rid="barth.REF.clarke.2013.23">Clarke et al [2013]</xref>
                </p>
              </fn>
              <fn id="barth.TF.1.3">
                <label>3. </label>
                <p>
                  <xref ref-type="bibr" rid="barth.REF.kelley.1991.738">Kelley et al [1991]</xref>
                </p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </sec>
        <sec id="barth.Establishing_the_Diagnosis">
          <title>Establishing the Diagnosis</title>
          <p>The diagnosis of Barth syndrome is established in a proband with either an increased monolysocardiolipin:cardiolipin ratio (if available) or detection of a <italic toggle="yes">TAZ</italic> pathogenic variant on molecular genetic testing (see <xref ref-type="table" rid="barth.T.summary_of_molecular_genetic_tes">Table 2</xref>).</p>
          <p><bold>Monolysocardiolipin:cardiolipin ratio.</bold> Since the protein that is deficient in Barth syndrome is responsible for cardiolipin (CL) remodeling within the inner mitochondrial membrane, affected individuals have (in a variety of tissues):</p>
          <list list-type="bullet">
            <list-item>
              <p>Increased monolysocardiolipins (MLCL);</p>
            </list-item>
            <list-item>
              <p>Decreased cardiolipins (specifically tetralinoleylcardiolipin, L4-CL).</p>
            </list-item>
          </list>
          <p>Using high-performance liquid chromatography-mass spectrometry (HPLC-MS), <xref ref-type="bibr" rid="barth.REF.van_werkhoven.2006.2346">van Werkhoven et al [2006]</xref> measured MLCL and CL levels from cultured fibroblasts of males with Barth syndrome and controls. They found that the range of MLCL:CL ratios in Barth syndrome was 5.41-13.83 and in controls was 0.03-0.12.</p>
          <p>Using a screening method in bloodspots, <xref ref-type="bibr" rid="barth.REF.kulik.2008.371">Kulik et al [2008]</xref> found that all males with Barth syndrome had an MLCL:CL ratio &#x0003e;0.40 and all controls had a ratio of &#x0003c;0.23. Using a cutoff of 0.30, they reported a sensitivity and specificity of 100%.</p>
          <list list-type="bullet">
            <list-item>
              <p>The same group later validated a confirmatory method in cultured fibroblasts, lymphocytes, and skeletal muscle [<xref ref-type="bibr" rid="barth.REF.houtkooper.2009.230">Houtkooper et al 2009</xref>].</p>
            </list-item>
            <list-item>
              <p>In a French study, all 16 affected males had an elevated MLCL:CL ratio&#x02013;in fibroblasts (14 individuals), in lymphoblasts (1 individual), and in platelets (1 individual) [<xref ref-type="bibr" rid="barth.REF.rigaud.2013.70">Rigaud et al 2013</xref>].</p>
            </list-item>
          </list>
          <sec id="barth.Molecular_Genetic_Testing">
            <title>Molecular Genetic Testing</title>
            <p>One molecular genetic testing strategy is testing of <italic toggle="yes">TAZ,</italic> the only gene in which pathogenic variants are known to cause Barth syndrome (<xref ref-type="table" rid="barth.T.summary_of_molecular_genetic_tes">Table 2</xref>).</p>
            <p>An alternative molecular genetic testing strategy is use of a multi-gene panel that includes <italic toggle="yes">TAZ</italic> and other genes of interest (see <xref ref-type="sec" rid="barth.Differential_Diagnosis">Differential Diagnosis</xref>). Note: The genes included and the methods used in multi-gene panels vary by laboratory and over time.</p>
            <table-wrap id="barth.T.summary_of_molecular_genetic_tes" orientation="portrait" position="anchor">
              <label>Table 2. </label>
              <caption>
                <p>Summary of Molecular Genetic Testing Used in Barth Syndrome</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_barth.T.summary_of_molecular_genetic_tes_1_1_1_1" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_barth.T.summary_of_molecular_genetic_tes_1_1_1_1">Gene&#x000a0;<sup>1</sup></th>
                    <th id="hd_h_barth.T.summary_of_molecular_genetic_tes_1_1_1_2" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_barth.T.summary_of_molecular_genetic_tes_1_1_1_2">Test Method</th>
                    <th id="hd_h_barth.T.summary_of_molecular_genetic_tes_1_1_1_3" valign="middle" colspan="2" align="left" scope="colgroup" rowspan="1">Proportion of Probands with a Pathogenic Variant Detectable by This Method</th>
                  </tr>
                  <tr>
                    <th headers="hd_h_barth.T.summary_of_molecular_genetic_tes_1_1_1_3" id="hd_h_barth.T.summary_of_molecular_genetic_tes_1_1_2_1" valign="middle" colspan="1" align="left" scope="colgroup" rowspan="1">Affected Males</th>
                    <th headers="hd_h_barth.T.summary_of_molecular_genetic_tes_1_1_1_3" id="hd_h_barth.T.summary_of_molecular_genetic_tes_1_1_2_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Heterozygous Females</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_barth.T.summary_of_molecular_genetic_tes_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                      <italic toggle="yes">TAZ</italic>
                    </td>
                    <td headers="hd_h_barth.T.summary_of_molecular_genetic_tes_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>2</sup></td>
                    <td headers="hd_h_barth.T.summary_of_molecular_genetic_tes_1_1_1_3 hd_h_barth.T.summary_of_molecular_genetic_tes_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">93.1%&#x000a0;<sup>3,&#x000a0;4</sup></td>
                    <td headers="hd_h_barth.T.summary_of_molecular_genetic_tes_1_1_1_3 hd_h_barth.T.summary_of_molecular_genetic_tes_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">91.7%&#x000a0;<sup>4,&#x000a0;5,&#x000a0;6</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_barth.T.summary_of_molecular_genetic_tes_1_1_1_2" valign="top" colspan="1" align="left" scope="row" rowspan="1">Deletion/duplication analysis&#x000a0;<sup>7</sup></td>
                    <td headers="hd_h_barth.T.summary_of_molecular_genetic_tes_1_1_1_3 hd_h_barth.T.summary_of_molecular_genetic_tes_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">6.9%&#x000a0;<sup>4</sup></td>
                    <td headers="hd_h_barth.T.summary_of_molecular_genetic_tes_1_1_1_3 hd_h_barth.T.summary_of_molecular_genetic_tes_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">8.3%&#x000a0;<sup>4,&#x000a0;6,&#x000a0;8</sup></td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="barth.TF.2.1">
                  <label>1. </label>
                  <p>See <related-object source-id="gene" document-id="barth" object-id="barth.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein. See <xref ref-type="sec" rid="barth.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants.</p>
                </fn>
                <fn id="barth.TF.2.2">
                  <label>2. </label>
                  <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
                </fn>
                <fn id="barth.TF.2.3">
                  <label>3. </label>
                  <p>Lack of amplification by PCR prior to sequence analysis can suggest a putative (multi)exon or whole-gene deletion on the X chromosome in affected males; confirmation may require additional testing by deletion/duplication analysis.</p>
                </fn>
                <fn id="barth.TF.2.4">
                  <label>4. </label>
                  <p>Based on <xref ref-type="bibr" rid="barth.REF.stenson.2003.577">Stenson et al [2003]</xref> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.barthsyndrome.org/science--medicine/human-taz-gene-variants-database">Human Tafazzin (TAZ) Gene Mutation &#x00026; Variation Database</ext-link></p>
                </fn>
                <fn id="barth.TF.2.5">
                  <label>5. </label>
                  <p>Sequence analysis of genomic DNA cannot detect deletion of one or more exons or the entire X-linked gene in a heterozygous female.</p>
                </fn>
                <fn id="barth.TF.2.6">
                  <label>6. </label>
                  <p>These are estimates, as large-scale studies on carrier females have not been carried out.</p>
                </fn>
                <fn id="barth.TF.2.7">
                  <label>7. </label>
                  <p>Testing that identifies exon or whole-gene deletions/duplications not detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA. Included in the variety of methods that may be used are: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and chromosomal microarray (CMA) that includes this gene/chromosome segment.</p>
                </fn>
                <fn id="barth.TF.2.8">
                  <label>8. </label>
                  <p>A single affected female was found to have a mosaic ring chromosome X, with a deletion of the Xq28 region containing <italic toggle="yes">TAZ</italic>.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </sec>
        </sec>
      </sec>
      <sec id="barth.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="barth.Clinical_Description">
          <title>Clinical Description</title>
          <p>Although Barth syndrome is classically characterized by cardiomyopathy, neutropenia, skeletal myopathy, prepubertal growth delay, and characteristic dysmorphic features, any given patient may not have all of these features.</p>
          <p>In a French study of 22 males with Barth syndrome from 16 families, the median age at which medical care was first sought was 3.1 weeks (range: 0-1.4 years) [<xref ref-type="bibr" rid="barth.REF.rigaud.2013.70">Rigaud et al 2013</xref>].</p>
          <p>In another study of 73 males enrolled in the Barth Syndrome Registry, the age of onset was 0.76 &#x000b1; 1.6 years and the mean age at diagnosis was 4.04 &#x000b1; 5.45 years [<xref ref-type="bibr" rid="barth.REF.roberts.2012.2726">Roberts et al 2012</xref>]. Therefore, there is on average a three-year delay between presentation and diagnosis of Barth syndrome. Cardiomyopathy was the presenting manifestation in 73% and infection was the presenting manifestation in 18%.</p>
          <p><bold>Cardiomyopathy</bold> in Barth syndrome is usually dilated cardiomyopathy but can also have features of combined dilated and hypertrophic cardiomyopathy, or isolated hypertrophic cardiomyopathy. Left ventricular noncompaction is also seen in many affected males.</p>
          <p>In the French study of 11 males with echocardiograms available at diagnosis:</p>
          <list list-type="bullet">
            <list-item>
              <p>Seven had left ventricular noncompaction,</p>
            </list-item>
            <list-item>
              <p>Six had dilated cardiomyopathy and hypertrophic cardiomyopathy,</p>
            </list-item>
            <list-item>
              <p>Two had dilated cardiomyopathy,</p>
            </list-item>
            <list-item>
              <p>One had hypertrophic cardiomyopathy.</p>
            </list-item>
          </list>
          <p>The cardiomyopathy characteristically follows an undulating course in which the cardiac tissue can undergo remodeling, including a transition between hypertrophic and dilated appearances.</p>
          <p>Cardiomyopathy almost always presents before age five years [<xref ref-type="bibr" rid="barth.REF.clarke.2013.23">Clarke et al 2013</xref>]. In many affected individuals the cardiomyopathy improves and in some it stabilizes after the toddler years. In the French cohort, left ventricular size and mass increased during the first six months of life, then decreased until age two years, and then appeared to stabilize. Data were insufficient to characterize these parameters in older children.</p>
          <p><bold>Heart failure</bold> is a significant cause of morbidity and mortality; however, overall cardiac function varies greatly in individuals with Barth syndrome. <xref ref-type="bibr" rid="barth.REF.roberts.2012.2726">Roberts et al [2012]</xref> noted that there may be a trend towards decline in cardiac function over time, as data from the Barth Syndrome Registry showed that for each five-year increase in age, ejection fraction z-score decreases on average by 0.6.</p>
          <p>In the French study, out of 54 total hospitalizations for heart failure, 11 were due to worsening of heart failure attributed to infections. In this cohort, nine died from heart failure and two from sepsis. Median age of death was 5.1 months (range: 1.2-30.7 months).</p>
          <p>The response to medical therapy for cardiac failure is generally good. <xref ref-type="bibr" rid="barth.REF.spencer.2006.e337">Spencer et al [2006]</xref> observed that with standard cardiac medications for dilated cardiomyopathy more than 16/30 patients had normal ejection fraction and left ventricular diastolic volume. However, some patients responded to therapy initially but deteriorated after a period of stability, requiring cardiac transplantation [<xref ref-type="bibr" rid="barth.REF.adwani.1997.143">Adwani et al 1997</xref>, <xref ref-type="bibr" rid="barth.REF.mangat.2007.327">Mangat et al 2007</xref>].</p>
          <p><bold>Arrhythmia.</bold> The risk for arrhythmia (including supraventricular and ventricular tachycardia) and sudden death is increased. While arrhythmia has been most often reported in adolescents and young adults, it can occur in children of all ages. ECG abnormalities can include repolarization abnormalities and prolonged QTc intervals.</p>
          <p>All 20 patients with ECGs in the French cohort had a normal sinus rhythm. Repolarization abnormalities (including ST flattening and T-wave inversion) were seen in 17. Five had QTc values within the normal range (QTc&#x0003c;420 ms), and five had QTc greater than 460 ms. The median QTc was 440 ms (range: 360&#x02013;530 ms).</p>
          <p>In the five instances of ventricular arrhythmia leading to cardiac arrest or placement of an internal defibrillator [<xref ref-type="bibr" rid="barth.REF.spencer.2005.632">Spencer et al 2005</xref>]:</p>
          <list list-type="bullet">
            <list-item>
              <p>Five had normal QTc intervals.</p>
            </list-item>
            <list-item>
              <p>Five had a history of recurrent vasovagal symptoms including postural dizziness, nausea, and pallor suggestive of autonomic instability.</p>
            </list-item>
            <list-item>
              <p>Four had only mild LV dilatation and low normal to mildly depressed LV function; only one had poor but stable LV function prior to cardiac arrest.</p>
            </list-item>
            <list-item>
              <p>Three showed inducible ventricular arrhythmias on electrophysiologic testing.</p>
            </list-item>
            <list-item>
              <p>Two (and possibly 3) had a family history of sudden death in a brother suspected of having Barth syndrome. Of note, no genotype-phenotype correlations predicted increased risk for arrhythmia.</p>
            </list-item>
            <list-item>
              <p>One had a normal Holter monitor study; one had only repolarization abnormalities at higher heart rates.</p>
            </list-item>
            <list-item>
              <p>One had both ventricular and supraventricular tachycardia.</p>
            </list-item>
          </list>
          <p><bold>Neutropenia and infections.</bold> In the Barth Syndrome Registry study self-reported data revealed that neutropenia* was present in 69.1% at some point, a number similar to that from the French study in which 16 of 22 males had a median absolute neutrophil count (ANC) &#x0003c;500 cells/&#x000b5;L at least once.</p>
          <p>*Defined as follows:</p>
          <list list-type="bullet">
            <list-item>
              <p>Mild neutropenia. ANC between 1000 and 1500cells/&#x000b5;L</p>
            </list-item>
            <list-item>
              <p>Moderate neutropenia. ANC between 500 and 1000cells/&#x000b5;L</p>
            </list-item>
            <list-item>
              <p>Severe neutropenia. ANC&#x0003c;500 cells/&#x000b5;L</p>
            </list-item>
          </list>
          <p>In the original description of the syndrome by <xref ref-type="bibr" rid="barth.REF.barth.1983.327">Barth et al [1983]</xref> three of seven males with a known cause of death died from infection; however, such high mortality from infection was not observed in subsequent publications. In fact, the effects of neutropenia are more often limited to mild involvement, such as persistent oral infections [<xref ref-type="bibr" rid="barth.REF.barth.1999.273">Barth et al 1999</xref>]. In the more recent Barth Syndrome Registry study, 60.2% of affected males had mouth ulcers, 28% had pneumonia, and 10% had blood infections.</p>
          <p>This relatively low incidence of bacterial infections despite an ANC persistently below 1000 cells/&#x000b5;L could be due to the development of a chronic, substantial monocytosis [<xref ref-type="bibr" rid="barth.REF.kelley.2002">Kelley 2002</xref>], which has been reported in two recent studies:</p>
          <list list-type="bullet">
            <list-item>
              <p>In the French study the median absolute monocyte count (AMC) was 1100 cells/&#x000b5;L (range: 500-4300 cells/&#x000b5;L).</p>
            </list-item>
            <list-item>
              <p><xref ref-type="bibr" rid="barth.REF.vernon.2014.143">Vernon et al [2014]</xref> reported that the average AMC was 894 &#x000b1; 449 cells/&#x000b5;L (range: 500-2400 cells/&#x000b5;L), with five of 17 affected males having monocyte counts at or above 1000 cells/&#x000b5;L.</p>
            </list-item>
          </list>
          <p>Of note, hematologic parameters neither worsen nor improve with age [<xref ref-type="bibr" rid="barth.REF.dale.2013">Dale et al 2013</xref>].</p>
          <p><bold>Skeletal myopathy,</bold> which predominantly affects the proximal muscles, is non-progressive during childhood [<xref ref-type="bibr" rid="barth.REF.clarke.2013.23">Clarke et al 2013</xref>]. Frequently, affected children are diagnosed with hypotonia.</p>
          <list list-type="bullet">
            <list-item>
              <p>In the Barth Syndrome Registry study it was observed that the myopathy led to developmental motor delay: 44 of 67 children showed a delay in sitting up, and 48 of 67 showed a delay in walking. Of note, 34% of affected males reported the use of foot and/or ankle orthoses, walkers, or wheelchairs at some point in their lives.</p>
            </list-item>
            <list-item>
              <p>In the French study the median age for walking was 19 months (range: 12-24 months).</p>
            </list-item>
          </list>
          <p>Some males with Barth syndrome were born with talipes equinovarus, indicating a possible prenatal onset of hypotonia [<xref ref-type="bibr" rid="barth.REF.ad_s.1993.327">Ad&#x000e8;s et al 1993</xref>, <xref ref-type="bibr" rid="barth.REF.gedeon.1995.383">Gedeon et al 1995</xref>].</p>
          <p>Of note, the exercise intolerance seen in males with Barth syndrome is due to both cardiac impairment and decreased skeletal muscle oxygen utilization [<xref ref-type="bibr" rid="barth.REF.spencer.2011.h2122">Spencer et al 2011</xref>].</p>
          <p><bold>Growth delay.</bold> Between ages six and 36 months the 50<sup>th</sup> percentile for weight for boys with Barth syndrome is roughly equivalent to the third percentile in the standard curve; between ages 27 and 36 months, the 50<sup>th</sup> percentile for weight is roughly equal to the third percentile in the standard curve [<xref ref-type="bibr" rid="barth.REF.roberts.2012.2726">Roberts et al 2012</xref>].</p>
          <p><xref ref-type="bibr" rid="barth.REF.roberts.2012.2726">Roberts et al [2012]</xref> published specific growth curves for boys with Barth syndrome [<xref ref-type="bibr" rid="barth.REF.roberts.2012.2726">Roberts et al 2012</xref>; see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://onlinelibrary.wiley.com/doi/10.1002/ajmg.a.35609/epdf">Figure 1a-d</ext-link>].</p>
          <p><xref ref-type="bibr" rid="barth.REF.spencer.2006.e337">Spencer et al [2006]</xref> found that males with Barth syndrome show a delayed post-pubertal growth spurt with remarkable &#x0201c;catch-up&#x0201d; growth.</p>
          <p>In males age &#x02264;18 years:</p>
          <list list-type="bullet">
            <list-item>
              <p>Mean weight is in the 15th percentile (range: &#x0003c;1-66) with 15 of 26 males below the fifth percentile. Mean height is in the eighth percentile (range: &#x0003c;1-38) with 15 of 26 males at or below the fifth percentile.</p>
            </list-item>
            <list-item>
              <p>Body mass index (BMI) is below the fifth percentile in 44% of males, normal in 48%, and above the 95th percentile in 7%.</p>
            </list-item>
          </list>
          <p>In males age &#x0003e;18 years, mean weight was in the 13<sup>th</sup> percentile (range: &#x0003c;1-63) and mean height in the 50<sup>th</sup> percentile (range: 8-90).</p>
          <p><bold>Dysmorphology.</bold> Younger males with Barth syndrome have a characteristic facial gestalt that is most evident during infancy, characterized by a tall and broad forehead, round face, full cheeks, prominent pointed chin, large ears, and deep-set eyes. This appearance persists through childhood, becoming less obvious following puberty. The ears tend to remain prominent and the eyes deep-set.</p>
          <p>At this point and after the late pubertal period of &#x0201c;catch-up&#x0201d; growth the most striking feature is that of gynoid fat distribution [<xref ref-type="bibr" rid="barth.REF.hastings.2009.185">Hastings et al 2009</xref>].</p>
          <p><bold>Intellectual development.</bold> Cognition in boys with Barth syndrome is characterized by age-appropriate vocabulary and basic reading skills, but a below-average performance in mathematics and selective difficulties in visuo-spatial skills that is not due to impaired motor functioning from myopathy [<xref ref-type="bibr" rid="barth.REF.mazzocco.2007.22">Mazzocco et al 2007</xref>]. Math difficulties are not evident in preschool but appear to emerge in kindergarten [<xref ref-type="bibr" rid="barth.REF.raches.2012.328">Raches &#x00026; Mazzocco 2012</xref>].</p>
          <p>In the Barth Syndrome Registry study, 30 of 60 males older than age three years reported delay either in first words or in putting words together; 31 of 67 participated in speech therapy. Twenty-two of 46 males older than age seven years reported some form of &#x0201c;learning disability.&#x0201d;</p>
          <p>Sensory issues related to feeding and eating are common, and many patients have a strong preference for salty, cheesy, and spicy foods while having an overall restricted repertoire of foods. Some issues such as a strong gag reflex manifest early in development [<xref ref-type="bibr" rid="barth.REF.reynolds.2012.1647">Reynolds et al 2012</xref>].</p>
          <p><bold>Psychosocial functioning.</bold> Boys with Barth syndrome experience lower quality of life than both healthy controls and boys with cardiac disease alone [<xref ref-type="bibr" rid="barth.REF.storch.2009.137">Storch et al 2009</xref>]. Nine of 34 children were being monitored by a school psychologist, and eight of 34 children had close contact with a school counselor.</p>
          <p><bold>Acute decompensation.</bold> An acute metabolic presentation with metabolic acidosis, elevated plasma lactate, elevated transaminases, hypoglycemia, and hyperammonemia has been reported [<xref ref-type="bibr" rid="barth.REF.donati.2006.684">Donati et al 2006</xref>]. Of note, this presentation has been described even in the setting of largely preserved cardiac function [<xref ref-type="bibr" rid="barth.REF.yen.2008.941">Yen et al 2008</xref>, <xref ref-type="bibr" rid="barth.REF.steward.2010.970">Steward et al 2010</xref>]. All four males reported to date with this metabolic presentation had onset of symptoms during the neonatal period (between days 1 and 13). Their subsequent course is not known to differ from that of other males with Barth syndrome.</p>
          <p><bold>Other.</bold> Based on data collected by the Barth Syndrome Registry study, other observed findings were:</p>
          <list list-type="bullet">
            <list-item>
              <p>Delayed bone age (in 58%);</p>
            </list-item>
            <list-item>
              <p>Scoliosis (in 20%);</p>
            </list-item>
            <list-item>
              <p>Supplemental feeds via either gastrostomy tube or nasogastric tube (in 23 of 70 individuals).</p>
            </list-item>
          </list>
          <p><bold>Perinatal.</bold> In 19 families with Barth syndrome, <xref ref-type="bibr" rid="barth.REF.steward.2010.970">Steward et al [2010]</xref> found that six had serious perinatal issues including male fetal loss, nine stillbirths, and severe neonatal illness or death. The authors noted that Barth syndrome may be an under-recognized cause of male fetal loss. Others have described characteristic cardiac pathology of Barth syndrome (endocardial fibroelastosis and subendocardial vacuolization of myocytes) as early as 18 weeks&#x02019; gestation [<xref ref-type="bibr" rid="barth.REF.brady.2006.462">Brady et al 2006</xref>].</p>
          <p>In the Barth Syndrome Registry study, pre-term birth from 29 to 36 weeks occurred in nine of 65 males; birth weight was &#x0003c;2.5 kg in nine of 48 males.</p>
          <p>In the French study, median birth weight was 2770 g (range: 2180-3730 g) and seven of 22 males had severe intrauterine growth restriction with birth weight below the third percentile.</p>
          <p><bold>Survival.</bold> The two factors that correlate with survival are severe neutropenia at the time of diagnosis and birth year (before 2000 or in/after 2000) [<xref ref-type="bibr" rid="barth.REF.rigaud.2013.70">Rigaud et al 2013</xref>].</p>
          <p>Males with an ANC &#x0003c;500 cells/&#x000b5;L at the time of diagnosis have a one-year survival rate of 25% compared to 68% for those with an ANC &#x0003e;500 cells/&#x000b5;L.</p>
          <p>Males born before 2000 had a five-year survival rate of 22% compared to 70% in those born in or after 2000. This finding is likely related to the better management of heart failure in more recent years.</p>
          <p>In the French study, the five-year survival rate was 51%, with no deaths reported in males age three years or older; thus, the risk for early mortality appears to peak in the first few years of life.</p>
          <p><xref ref-type="bibr" rid="barth.REF.ronvelia.2012.428">Ronvelia et al [2012]</xref> report a man age 51 years with Barth syndrome (the oldest living individual with a confirmed diagnosis) and mention anecdotally two affected males, one in his 40s and one in his 60s.</p>
          <p><bold>Laboratory findings</bold> that may be found in association with Barth syndrome:</p>
          <list list-type="bullet">
            <list-item>
              <p>Lactic acidosis. Blood lactate ranges from normal to well above normal related to both cardiac and metabolic status (normal: 0.5-2.2 mmol/L).</p>
            </list-item>
            <list-item>
              <p>Plasma amino acids</p>
              <list list-type="bullet">
                <list-item>
                  <p>In a French study in which plasma amino acid levels were available for eight affected males, all showed lower arginine levels than controls [<xref ref-type="bibr" rid="barth.REF.rigaud.2013.70">Rigaud et al 2013</xref>].</p>
                </list-item>
                <list-item>
                  <p>This finding was reproduced in 28 males with Barth syndrome (mean arginine level 43 &#x003bc;mol/L) vs controls (70 &#x003bc;mol/L) with a statistically significant p-value [<xref ref-type="bibr" rid="barth.REF.vernon.2014.143">Vernon et al 2014</xref>]. These 28 males also showed significantly higher proline levels (291 &#x003bc;mol/L) than controls (165 &#x003bc;mol/L).</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Hypocholesterolemia (total cholesterol &#x0003c;110 mg/dL). Described in six of 25 patients tested [<xref ref-type="bibr" rid="barth.REF.spencer.2006.e337">Spencer et al 2006</xref>]. In another study, only two of 28 were found to be hypocholesterolemic, with a mean cholesterol level of 137 &#x000b1; 26 mg/dL [<xref ref-type="bibr" rid="barth.REF.vernon.2014.143">Vernon et al 2014</xref>].</p>
            </list-item>
            <list-item>
              <p>Hypoglycemia. Although not a common finding, hypoglycemia has been described occasionally [<xref ref-type="bibr" rid="barth.REF.kelley.1991.738">Kelley et al 1991</xref>, <xref ref-type="bibr" rid="barth.REF.christodoulou.1994.255">Christodoulou et al 1994</xref>] and in at least one case was the presenting complaint [<xref ref-type="bibr" rid="barth.REF.rigaud.2013.70">Rigaud et al 2013</xref>].</p>
            </list-item>
            <list-item>
              <p>Creatine kinase. Mild elevations ranging from 192 to 397 mg/dL have been reported in three of 20 males tested [<xref ref-type="bibr" rid="barth.REF.spencer.2006.e337">Spencer et al 2006</xref>].</p>
            </list-item>
            <list-item>
              <p>Prealbumin. Low prealbumin (&#x0003c;20 mg/dL) has been described in 15 of 19 males tested [<xref ref-type="bibr" rid="barth.REF.spencer.2006.e337">Spencer et al 2006</xref>]. In a separate study 13 of 18 affected males showed decreased prealbumin levels with a mean of 16.9 &#x000b1; 4.0 mg/dL [<xref ref-type="bibr" rid="barth.REF.vernon.2014.143">Vernon et al 2014</xref>].</p>
            </list-item>
          </list>
          <p><bold>Respiratory chain studies</bold> reveal decreased activity of complex III and IV in skeletal muscle [<xref ref-type="bibr" rid="barth.REF.barth.1983.327">Barth et al 1983</xref>] and fibroblasts [<xref ref-type="bibr" rid="barth.REF.barth.1996.157">Barth et al 1996</xref>].</p>
          <p>
            <bold>Pathology</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Skeletal muscle. Accumulation of lipid droplets within type I muscle fibers and nonspecific mitochondrial abnormalities have been described [<xref ref-type="bibr" rid="barth.REF.barth.1983.327">Barth et al 1983</xref>, <xref ref-type="bibr" rid="barth.REF.ino.1988.511">Ino et al 1988</xref>, <xref ref-type="bibr" rid="barth.REF.kelley.1991.738">Kelley et al 1991</xref>]. In at least one case the initial presentation was alipid storage myopathy [<xref ref-type="bibr" rid="barth.REF.takeda.2011.1481">Takeda et al 2011</xref>].</p>
            </list-item>
            <list-item>
              <p>Liver. Lipid storage in the liver has also been described [<xref ref-type="bibr" rid="barth.REF.ino.1988.511">Ino et al 1988</xref>, <xref ref-type="bibr" rid="barth.REF.kelley.1991.738">Kelley et al 1991</xref>, <xref ref-type="bibr" rid="barth.REF.donati.2006.684">Donati et al 2006</xref>].</p>
            </list-item>
            <list-item>
              <p>Bone marrow</p>
              <list list-type="bullet">
                <list-item>
                  <p>A maturation arrest at the myelocyte stage was noted in the original description of the disease [<xref ref-type="bibr" rid="barth.REF.barth.1983.327">Barth et al 1983</xref>].</p>
                </list-item>
                <list-item>
                  <p>More recently, in a French cohort in which five bone marrow smears were available, two showed promyelocyte-myelocyte maturation arrest, and the samples without a complete arrest showed an increased proportion of promyelocytes with a greatly decreased proportion of myelocytes, metamyelocytes, and neutrophils [<xref ref-type="bibr" rid="barth.REF.rigaud.2013.70">Rigaud et al 2013</xref>].</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <p><bold>Female heterozygotes</bold> do not manifest the disease. Biochemical abnormalities have not been found in eight female carriers [<xref ref-type="bibr" rid="barth.REF.vernon.2014.143">Vernon et al 2014</xref>].</p>
          <p>It is proposed that female carriers are healthy due to selection against cells with the mutated <italic toggle="yes">TAZ</italic> allele on the active X chromosome, based on the study of the X-chromosome inactivation pattern in 16 obligate carriers [<xref ref-type="bibr" rid="barth.REF.orstavik.1998.1457">Orstavik et al 1998</xref>]. In this study, six of the 16 had an extremely skewed pattern of X-chromosome inactivation (&#x02265;95:5) and five had a skewed pattern (80:20-&#x0003c;95:5) which was not observed in 148 female controls.</p>
          <p>The only female reported with Barth syndrome had biallelic changes in <italic toggle="yes">TAZ</italic> as a result of (1) a complete deletion of the paternal allele (associated with a ring X chromosome with a large deletion that included <italic toggle="yes">TAZ</italic>) and (2) a deletion of exons 1-5 in the maternal <italic toggle="yes">TAZ</italic> allele [<xref ref-type="bibr" rid="barth.REF.cosson.2012.115">Cosson et al 2012</xref>]. Analysis of lymphocyte and fibroblast cultures showed monosomy X with mosaicism for the ring X chromosome; thus, at least in lymphocytes, she lacked a normal <italic toggle="yes">TAZ</italic> allele.</p>
        </sec>
        <sec id="barth.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>No genotype-phenotype correlations are known [<xref ref-type="bibr" rid="barth.REF.johnston.1997.1053">Johnston et al 1997</xref>, <xref ref-type="bibr" rid="barth.REF.rigaud.2013.70">Rigaud et al 2013</xref>].</p>
        </sec>
        <sec id="barth.Penetrance">
          <title>Penetrance</title>
          <p>Although the question of the penetrance of Barth syndrome has never been formally evaluated, it is thought that males manifest complete penetrance, although with variable expressivity.</p>
          <p>Female carriers with a normal 46,XX karyotype do not manifest the disease (see <xref ref-type="sec" rid="barth.Clinical_Description">Clinical Description</xref>, <bold>Female heterozygotes</bold>).</p>
        </sec>
        <sec id="barth.Prevalence">
          <title>Prevalence</title>
          <p>As of 2013, 151 males with Barth syndrome were recorded worldwide.</p>
          <list list-type="bullet">
            <list-item>
              <p>It is estimated that fewer than ten new patients are diagnosed with Barth syndrome in the United States each year, suggesting an incidence of 1:300,000-1:400,000 births [<xref ref-type="bibr" rid="barth.REF.kelley.2002">Kelley 2002</xref>].</p>
            </list-item>
            <list-item>
              <p><xref ref-type="bibr" rid="barth.REF.clarke.2013.23">Clarke et al [2013]</xref> calculated an incidence potentially as high as 1:140,000 live births in South West England and South Wales.</p>
            </list-item>
            <list-item>
              <p><xref ref-type="bibr" rid="barth.REF.rigaud.2013.70">Rigaud et al [2013]</xref> estimated an incidence of 1.5 cases per million births (95% CI: 0.2-2.3) based on data from France between 1995 and 2008; they noted, however, that some patients may have been undiagnosed either due to a mild clinical course or sudden unexplained death.</p>
            </list-item>
          </list>
          <p>Barth syndrome shows no ethnic or racial predilection, as it has been described throughout the world.</p>
        </sec>
      </sec>
      <sec id="barth.Genetically_Related_Allelic_Disord">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>Isolated left ventricular noncompaction has been associated with various pathogenic variants in <italic toggle="yes">TAZ</italic> [<xref ref-type="bibr" rid="barth.REF.bleyl.1997.257">Bleyl et al 1997</xref>, <xref ref-type="bibr" rid="barth.REF.ichida.2001.1256">Ichida et al 2001</xref>, <xref ref-type="bibr" rid="barth.REF.chen.2002.319">Chen et al 2002</xref>]; however, this is a rare occurrence [<xref ref-type="bibr" rid="barth.REF.kenton.2004.162">Kenton et al 2004</xref>].</p>
      </sec>
      <sec id="barth.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p><bold>Disorders in which excretion of 3-methylglutaconate (3-MGC) is increased.</bold> Increased urinary excretion of the branched-chain organic acid 3-methylglutaconate (3-MGC) is a relatively common finding in children investigated for suspected inborn errors of metabolism [<xref ref-type="bibr" rid="barth.REF.gunayaygun.2005.1">Gunay-Aygun 2005</xref>]. 3-MGC is an intermediate of leucine degradation and the mevalonate shunt pathway that links sterol synthesis with mitochondrial acetyl-CoA metabolism.</p>
        <p>Classification of inborn errors of metabolism with 3-methylglutaconic aciduria as a discriminative feature has recently been updated [<xref ref-type="bibr" rid="barth.REF.wortmann.2013.923">Wortmann et al 2013</xref>, <xref ref-type="bibr" rid="barth.REF.wortmann.2015.99">Wortmann et al 2015</xref>] (<xref ref-type="table" rid="barth.T.new_classification_for_inborn_er">Table 3</xref>).</p>
        <p>Clinical features (<xref ref-type="table" rid="barth.T.new_classification_for_inborn_er">Table 3</xref>) and biochemical findings (<xref ref-type="table" rid="barth.T.urinary_excretion_of_3mgc_and_3m">Table 4</xref>) of the 3-MGCA syndromes vary. Tissues with higher requirements for oxidative metabolism, such as the central nervous system and cardiac and skeletal muscle, are predominantly affected.</p>
        <table-wrap id="barth.T.new_classification_for_inborn_er" orientation="portrait" position="anchor">
          <label>Table 3. </label>
          <caption>
            <p>New Classification for Inborn Errors of Metabolism with 3-MethylglutaconicAciduria as Discriminative Feature</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_barth.T.new_classification_for_inborn_er_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Group</th>
                <th id="hd_h_barth.T.new_classification_for_inborn_er_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Patho-Mechanism</th>
                <th id="hd_h_barth.T.new_classification_for_inborn_er_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Disease Name</th>
                <th id="hd_h_barth.T.new_classification_for_inborn_er_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Former Designation</th>
                <th id="hd_h_barth.T.new_classification_for_inborn_er_1_1_1_5" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Additional Hallmarks&#x000a0;<sup>1</sup> of Phenotype</th>
                <th id="hd_h_barth.T.new_classification_for_inborn_er_1_1_1_6" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Affected Gene / Protein / Subcellular Localization / Proposed Function</th>
                <th id="hd_h_barth.T.new_classification_for_inborn_er_1_1_1_7" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Mode of Inheritance</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_barth.T.new_classification_for_inborn_er_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Primary 3-MGA-uria</td>
                <td headers="hd_h_barth.T.new_classification_for_inborn_er_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Organic aciduria</td>
                <td headers="hd_h_barth.T.new_classification_for_inborn_er_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">3-methylglutaconyl-CoA hydratase deficiency (<italic toggle="yes">AUH</italic> defect)</td>
                <td headers="hd_h_barth.T.new_classification_for_inborn_er_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">3-MGCA type I<break/>(3-MGCA-1)</td>
                <td headers="hd_h_barth.T.new_classification_for_inborn_er_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Adult-onset leukoencephalopathy, dementia, progressive spasticity</td>
                <td headers="hd_h_barth.T.new_classification_for_inborn_er_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1"><italic toggle="yes">AUH</italic> / 3-methylglutaconyl-CoA hydratase / mitochondrial matrix / leucine catabolism</td>
                <td headers="hd_h_barth.T.new_classification_for_inborn_er_1_1_1_7" valign="middle" align="left" rowspan="1" colspan="1">AR</td>
              </tr>
              <tr>
                <td headers="hd_h_barth.T.new_classification_for_inborn_er_1_1_1_1" rowspan="6" valign="middle" align="left" scope="row" colspan="1">Secondary 3-MGA-uria</td>
                <td headers="hd_h_barth.T.new_classification_for_inborn_er_1_1_1_2" rowspan="2" valign="middle" align="left" colspan="1">Defective phospholipid remodeling</td>
                <td headers="hd_h_barth.T.new_classification_for_inborn_er_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"><italic toggle="yes">TAZ</italic> defect (Barth syndrome)</td>
                <td headers="hd_h_barth.T.new_classification_for_inborn_er_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">3-MGCA type II<break/>(3-MGCA-2)</td>
                <td headers="hd_h_barth.T.new_classification_for_inborn_er_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">(Cardio)myopathy, short stature, neutropenia, hypocholesterolemia, cognitive phenotype, mild dysmorphic features, OXPHOS dysfunction</td>
                <td headers="hd_h_barth.T.new_classification_for_inborn_er_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1"><italic toggle="yes">TAZ</italic> / tafazzin / (inner) mitochondrial membrane / cardiolipin remodeling</td>
                <td headers="hd_h_barth.T.new_classification_for_inborn_er_1_1_1_7" valign="middle" align="left" rowspan="1" colspan="1">XL</td>
              </tr>
              <tr>
                <td headers="hd_h_barth.T.new_classification_for_inborn_er_1_1_1_3" valign="middle" colspan="1" align="left" scope="row" rowspan="1"><italic toggle="yes">SERAC1</italic> defect (<related-object link-type="booklink" source-id="gene" document-id="megdel" document-type="chapter">MEGDEL syndrome</related-object>)</td>
                <td headers="hd_h_barth.T.new_classification_for_inborn_er_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">3-MGCA type IV<break/>(3-MGCA-4)</td>
                <td headers="hd_h_barth.T.new_classification_for_inborn_er_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Progressive spasticity, dystonia, deafness, Leigh syndrome-like MRI, severe psychomotor retardation, hypocholesterolemia, OXPHOS dysfunction</td>
                <td headers="hd_h_barth.T.new_classification_for_inborn_er_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1"><italic toggle="yes">SERAC1</italic> / SERAC1 / mitochondria-associated membranes fraction / phosphatidyl-glycerol remodeling, cardiolipin composition</td>
                <td headers="hd_h_barth.T.new_classification_for_inborn_er_1_1_1_7" valign="middle" align="left" rowspan="1" colspan="1">AR</td>
              </tr>
              <tr>
                <td headers="hd_h_barth.T.new_classification_for_inborn_er_1_1_1_2" rowspan="3" valign="middle" colspan="1" align="left" scope="row">Mitochondrial membrane disorder</td>
                <td headers="hd_h_barth.T.new_classification_for_inborn_er_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"><italic toggle="yes">OPA3</italic> defect (<related-object link-type="booklink" source-id="gene" document-id="mga3" document-type="chapter">Costeff syndrome</related-object>)</td>
                <td headers="hd_h_barth.T.new_classification_for_inborn_er_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">3-MGCA type III<break/>(3-MGCA-3)</td>
                <td headers="hd_h_barth.T.new_classification_for_inborn_er_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Ataxia/extrapyramidal dysfunction, optic atrophy</td>
                <td headers="hd_h_barth.T.new_classification_for_inborn_er_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1"><italic toggle="yes">OPA3</italic> / optic atrophy 3 protein / outer mitochondrial membrane / ?protective function for respiratory chain</td>
                <td headers="hd_h_barth.T.new_classification_for_inborn_er_1_1_1_7" valign="middle" align="left" rowspan="1" colspan="1">AR</td>
              </tr>
              <tr>
                <td headers="hd_h_barth.T.new_classification_for_inborn_er_1_1_1_3" valign="middle" colspan="1" align="left" scope="row" rowspan="1"><italic toggle="yes">TMEM70</italic> defect</td>
                <td headers="hd_h_barth.T.new_classification_for_inborn_er_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">3-MGCA type IV<break/>(3-MGCA-4)</td>
                <td headers="hd_h_barth.T.new_classification_for_inborn_er_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Broad phenotype, hypertrophic cardiomyopathy, myopathy, dysmorphic features, cataracts, psychomotor retardation, ATPase deficiency, lactic acidosis, hyperammonemia</td>
                <td headers="hd_h_barth.T.new_classification_for_inborn_er_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1"><italic toggle="yes">TMEM70</italic> / transmembrane protein 70, mitochondrial / inner mitochondrial membrane / ?complex V assembly and insertion in mitochondrial membrane</td>
                <td headers="hd_h_barth.T.new_classification_for_inborn_er_1_1_1_7" valign="middle" align="left" rowspan="1" colspan="1">AR</td>
              </tr>
              <tr>
                <td headers="hd_h_barth.T.new_classification_for_inborn_er_1_1_1_3" valign="middle" colspan="1" align="left" scope="row" rowspan="1"><italic toggle="yes">DNAJC19</italic> defect (DCMA syndrome)</td>
                <td headers="hd_h_barth.T.new_classification_for_inborn_er_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">3-MGCA type V<break/>(3-MGCA-5)</td>
                <td headers="hd_h_barth.T.new_classification_for_inborn_er_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Dilated cardiomyopathy, ECG abnormalities, non-progressive cerebellar ataxia, small atrophic testes, cryptorchidism, growth failure, anemia, steatosis hepatitis</td>
                <td headers="hd_h_barth.T.new_classification_for_inborn_er_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1"><italic toggle="yes">DNAJC19</italic> / mitochondrial import inner membrane translocase subunit TIM14 / ?inner mitochondrial membrane / ?mitochondrial protein import</td>
                <td headers="hd_h_barth.T.new_classification_for_inborn_er_1_1_1_7" valign="middle" align="left" rowspan="1" colspan="1">AR</td>
              </tr>
              <tr>
                <td headers="hd_h_barth.T.new_classification_for_inborn_er_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Unknown</td>
                <td headers="hd_h_barth.T.new_classification_for_inborn_er_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">NOS 3-MGA-uria</td>
                <td headers="hd_h_barth.T.new_classification_for_inborn_er_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">3-MGCA type IV<break/>(3-MGCA-4)</td>
                <td headers="hd_h_barth.T.new_classification_for_inborn_er_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Variable, mostly progressive neurologic disease</td>
                <td headers="hd_h_barth.T.new_classification_for_inborn_er_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">Unknown</td>
                <td headers="hd_h_barth.T.new_classification_for_inborn_er_1_1_1_7" valign="middle" align="left" rowspan="1" colspan="1">Unknown</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>From <xref ref-type="bibr" rid="barth.REF.wortmann.2013.923">Wortmann et al [2013]</xref></p>
            </fn>
            <fn>
              <p>DCMA = dilated cardiomyopathy with ataxia</p>
            </fn>
            <fn>
              <p>NOS= not otherwise specified</p>
            </fn>
            <fn id="barth.TF.3.1">
              <label>1. </label>
              <p>In addition to 3-MGA-uria</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p>See <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/phenotypicSeries/PS250950">3-Methylglutaconic Aciduria: OMIM Phenotypic Series</ext-link> to view genes associated with this phenotype in OMIM.</p>
        <table-wrap id="barth.T.urinary_excretion_of_3mgc_and_3m" orientation="portrait" position="anchor">
          <label>Table 4. </label>
          <caption>
            <p>Urinary Excretion of 3-MGC and 3-MGA in Inborn Errors of Metabolism with 3-Methylglutaconic Aciduria</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_barth.T.urinary_excretion_of_3mgc_and_3m_1_1_1_1" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_barth.T.urinary_excretion_of_3mgc_and_3m_1_1_1_1">Disorder</th>
                <th id="hd_h_barth.T.urinary_excretion_of_3mgc_and_3m_1_1_1_2" valign="middle" colspan="2" align="left" scope="colgroup" rowspan="1">Urinary Excretion</th>
              </tr>
              <tr>
                <th headers="hd_h_barth.T.urinary_excretion_of_3mgc_and_3m_1_1_1_2" id="hd_h_barth.T.urinary_excretion_of_3mgc_and_3m_1_1_2_1" valign="middle" colspan="1" align="left" scope="colgroup" rowspan="1">3-MGC and 3-MGA in mmol/mol Creatinine</th>
                <th headers="hd_h_barth.T.urinary_excretion_of_3mgc_and_3m_1_1_1_2" id="hd_h_barth.T.urinary_excretion_of_3mgc_and_3m_1_1_2_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">3-Hydroxyisovaleric Acid (3-HIV)</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_barth.T.urinary_excretion_of_3mgc_and_3m_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">3-methylglutaconyl-CoA hydratase deficiency</td>
                <td headers="hd_h_barth.T.urinary_excretion_of_3mgc_and_3m_1_1_1_2 hd_h_barth.T.urinary_excretion_of_3mgc_and_3m_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">500 to 1000&#x000a0;<sup>1</sup></td>
                <td headers="hd_h_barth.T.urinary_excretion_of_3mgc_and_3m_1_1_1_2 hd_h_barth.T.urinary_excretion_of_3mgc_and_3m_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Increased</td>
              </tr>
              <tr>
                <td headers="hd_h_barth.T.urinary_excretion_of_3mgc_and_3m_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">TAZ defect (Barth syndrome)</td>
                <td headers="hd_h_barth.T.urinary_excretion_of_3mgc_and_3m_1_1_1_2 hd_h_barth.T.urinary_excretion_of_3mgc_and_3m_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">Mild to moderate&#x000a0;<sup>2</sup></td>
                <td headers="hd_h_barth.T.urinary_excretion_of_3mgc_and_3m_1_1_1_2 hd_h_barth.T.urinary_excretion_of_3mgc_and_3m_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
              </tr>
              <tr>
                <td headers="hd_h_barth.T.urinary_excretion_of_3mgc_and_3m_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">OPA3 defect (Costeff syndrome)&#x000a0;<sup>3</sup></td>
                <td headers="hd_h_barth.T.urinary_excretion_of_3mgc_and_3m_1_1_1_2 hd_h_barth.T.urinary_excretion_of_3mgc_and_3m_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">9-187</td>
                <td headers="hd_h_barth.T.urinary_excretion_of_3mgc_and_3m_1_1_1_2 hd_h_barth.T.urinary_excretion_of_3mgc_and_3m_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
              </tr>
              <tr>
                <td headers="hd_h_barth.T.urinary_excretion_of_3mgc_and_3m_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">DNAJC19 defect (DCMA syndrome)</td>
                <td headers="hd_h_barth.T.urinary_excretion_of_3mgc_and_3m_1_1_1_2 hd_h_barth.T.urinary_excretion_of_3mgc_and_3m_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">Moderate&#x000a0;<sup>4</sup></td>
                <td headers="hd_h_barth.T.urinary_excretion_of_3mgc_and_3m_1_1_1_2 hd_h_barth.T.urinary_excretion_of_3mgc_and_3m_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
              </tr>
              <tr>
                <td headers="hd_h_barth.T.urinary_excretion_of_3mgc_and_3m_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">NOS 3-MGA-uria</td>
                <td headers="hd_h_barth.T.urinary_excretion_of_3mgc_and_3m_1_1_1_2 hd_h_barth.T.urinary_excretion_of_3mgc_and_3m_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">Elevated to variable degrees</td>
                <td headers="hd_h_barth.T.urinary_excretion_of_3mgc_and_3m_1_1_1_2 hd_h_barth.T.urinary_excretion_of_3mgc_and_3m_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
              </tr>
              <tr>
                <td headers="hd_h_barth.T.urinary_excretion_of_3mgc_and_3m_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Normal controls</td>
                <td headers="hd_h_barth.T.urinary_excretion_of_3mgc_and_3m_1_1_1_2 hd_h_barth.T.urinary_excretion_of_3mgc_and_3m_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">3.2-7</td>
                <td headers="hd_h_barth.T.urinary_excretion_of_3mgc_and_3m_1_1_1_2 hd_h_barth.T.urinary_excretion_of_3mgc_and_3m_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">NA</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="barth.TF.4.1">
              <label>1. </label>
              <p>The urinary excretion of 3-methylglutaric acid (3-MGA) correlates with protein intake, whereas in most individuals with other types of 3-MGCA the amount of 3-MGC in urine is not dependent on dietary leucine [<xref ref-type="bibr" rid="barth.REF.sweetman.2001">Sweetman &#x00026; Williams 2001</xref>].</p>
            </fn>
            <fn id="barth.TF.4.2">
              <label>2. </label>
              <p>Less than ten times the upper limit of normal</p>
            </fn>
            <fn id="barth.TF.4.3">
              <label>3. </label>
              <p>In 39 individuals [<xref ref-type="bibr" rid="barth.REF.elpeleg.1994.167">Elpeleg et al 1994</xref>]</p>
            </fn>
            <fn id="barth.TF.4.4">
              <label>4. </label>
              <p>Five- to tenfold normal [<xref ref-type="bibr" rid="barth.REF.davey.2006.385">Davey et al 2006</xref>]</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p><bold>Cardiomyopathy.</bold> Left ventricular noncompaction (LVNC) is seen in other genetic syndromes as an isolated finding or associated with other congenital cardiac malformations.</p>
        <p>Other genes in which pathogenic variants can lead to isolated cardiomyopathy with left ventricular noncompaction include: <italic toggle="yes">LDB3, ACTC1, MYH7, MIB1, PRDM16, TNNT2, TPM1,</italic> and <italic toggle="yes">MYBPC3.</italic> Given the considerable phenotypic overlap, it can be quite difficult to differentiate the phenotypes on the basis of specific genetic cause. However, as none of these other genes is on the X chromosome, a family history with a clear X-linked pattern of inheritance can point to Barth syndrome. Often, the most efficient way to determine the responsible gene is through molecular genetic testing using a multi-gene panel.</p>
        <p>Left ventricular noncompaction and skeletal myopathy can be seen in <related-object link-type="booklink" source-id="gene" document-id="dbmd" document-type="chapter">Duchenne muscular dystrophy</related-object>, with a prevalence as high as 28% [<xref ref-type="bibr" rid="barth.REF.statile.2013.67">Statile et al 2013</xref>]. However, in Duchenne muscular dystrophy, in contrast to Barth syndrome, the LVNC tends to worsen over time.</p>
        <p><bold>Neutropenia.</bold> The differential for isolated neutropenia is wide and includes several notable genetic conditions:</p>
        <list list-type="bullet">
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="cyclic-n" document-type="chapter"><italic toggle="yes">ELANE</italic>-related neutropenia</related-object> is an autosomal dominant disorder associated with either congenital neutropenia or cyclic neutropenia, both of which are primary hematologic disorders characterized by recurrent fever, skin and oropharyngeal inflammation (i.e., mouth ulcers, gingivitis, sinusitis, and pharyngitis), and cervical adenopathy.</p>
          </list-item>
          <list-item>
            <p>Kostmann syndrome is an autosomal recessive form of severe congenital neutropenia. <xref ref-type="bibr" rid="barth.REF.klein.2007.86">Klein et al [2007]</xref> identified homozygous pathogenic variants in <italic toggle="yes">HAX1</italic> (encoding HCLS1-associated protein X-1) in several individuals with Kostmann syndrome.</p>
          </list-item>
          <list-item>
            <p>Mutation of <italic toggle="yes">G6PC3</italic> (encoding glucose-6-phosphate 3) results in an autosomal recessive form of severe congenital neutropenia [<xref ref-type="bibr" rid="barth.REF.klein.2011.399">Klein 2011</xref>]. See <related-object link-type="booklink" source-id="gene" document-id="g6pc3-def" document-type="chapter">G6PC3 Deficiency</related-object>.</p>
          </list-item>
          <list-item>
            <p>Benign familial neutropenia is an autosomal dominant form of congenital neutropenia with milder neutropenia and less severe symptoms.</p>
          </list-item>
        </list>
      </sec>
      <sec id="barth.Management">
        <title>Management</title>
        <sec id="barth.Evaluations_Following_Initial_Diag">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and medical needs in an individual diagnosed with Barth syndrome, the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Complete blood count and differential</p>
            </list-item>
            <list-item>
              <p>Echocardiogram</p>
            </list-item>
            <list-item>
              <p>ECG</p>
            </list-item>
            <list-item>
              <p>Plasma amino acids</p>
            </list-item>
            <list-item>
              <p>Clinical genetics consultation</p>
            </list-item>
          </list>
        </sec>
        <sec id="barth.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p><bold>Management of heart failure.</bold> There is no specific treatment for cardiac dysfunction or arrhythmia in Barth syndrome. Standard heart failure (HF) medications are used to improve symptoms, effect reverse remodeling of the ventricle, and improve ventricular function as measured by ejection fraction (EF).</p>
          <p>These medications include ACE-inhibitors, beta blockers, and digoxin for typical outpatient management, and intravenous inotropes, including milrinone for in-patient management of acute decompensation.</p>
          <p>Therapy received by 22 individuals in the French cohort [<xref ref-type="bibr" rid="barth.REF.rigaud.2013.70">Rigaud et al 2013</xref>] included: 16/22 beta blockers, 9/22 beta blockers, 11/22 digoxin, 17/22 diuretics, 5/22 anticoagulants, and 5/22 aspirin.</p>
          <p>Although no studies are available to evaluate the effectiveness of medical therapy in males with Barth syndrome, when medications are stopped a decline in heart function is often observed. However, this can sometimes be difficult to distinguish from the natural fluctuations of the clinical phenotype (see Clinical Characteristics, <xref ref-type="sec" rid="barth.Clinical_Description">Clinical Description</xref>, <bold>Heart failure</bold>).</p>
          <p>Aspirin should be considered for prevention of clot formation (and thus reduction in the risk for stroke) in males with severe cardiac dysfunction and/or marked LVNC. Suggested aspirin dose is 5 mg/kg daily for children and 81 to 325 mg daily for adults.</p>
          <p>The potential role of prophylactic antiarrhythmic medication or implantable cardiac defibrillator for primary arrhythmia prevention has not been clarified.</p>
          <p>Cardiac transplantation has been successful when heart failure is severe and intractable [<xref ref-type="bibr" rid="barth.REF.mangat.2007.327">Mangat et al 2007</xref>, <xref ref-type="bibr" rid="barth.REF.roberts.2012.2726">Roberts et al 2012</xref>]; however, given the natural history of improving ventricular function after infancy, cardiac transplantation should be carefully considered.</p>
          <p><bold>Management of neutropenia.</bold> The treatment of neutropenia in children with Barth syndrome varies, including regular administration of granulocyte colony stimulating factor (G-CSF), administration of G-CSF during times of high risk only (e.g., surgery or infection), prophylactic antibiotics, and other preventive treatment strategies.</p>
          <p>Early on, it was suggested that the administration of G-CSF during times of suspected or known bacterial infection may be effective in reducing the incidence of severe infections [<xref ref-type="bibr" rid="barth.REF.cox.1995.a177">Cox et al 1995</xref>]. The usual starting dose of G-CSF is 2-3 &#x003bc;g/kg/dose with a frequency of administration ranging from twice a week to every other day [<xref ref-type="bibr" rid="barth.REF.clarke.2013.23">Clarke et al 2013</xref>].</p>
          <p>In 83 patients, 42 of whom had been treated with G-CSF, the median dose was 2.78 &#x000b1; 0.78 (SEM) &#x003bc;g/kg/dose (range: 0.45-12.8 &#x003bc;g/kg/dose) [<xref ref-type="bibr" rid="barth.REF.dale.2013">Dale et al 2013</xref>]. On average, G-CSF was begun at age 5.8 years, with an average exposure of 7.3 years; none developed acute myeloid leukemia, and treatment responses to G-CSF were maintained long-term.</p>
          <p>Of note, although neutropenia appears to improve with G-CSF treatment, in the French cohort in which six affected males were actively treated with G-CSF, two developed a severe infection, including one episode of septic shock [<xref ref-type="bibr" rid="barth.REF.rigaud.2013.70">Rigaud et al 2013</xref>].</p>
          <p><bold>Nutrition.</bold> Uncooked cornstarch given prior to bedtime has been recommended as a means of avoiding muscle protein loss overnight. Specific dosing according to age and weight can be obtained from the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.barthsyndrome.org/home">Barth Syndrome Foundation</ext-link> [<xref ref-type="bibr" rid="barth.REF.avery.2006">Avery 2006</xref>].</p>
          <p><bold>Educational support in school.</bold> The excessive fatigue that boys with Barth syndrome experience and the characteristic cognitive phenotype (see Clinical Characteristics, <xref ref-type="sec" rid="barth.Clinical_Description">Clinical Description</xref>) warrant educational support during the early school-age years [<xref ref-type="bibr" rid="barth.REF.mazzocco.2007.22">Mazzocco et al 2007</xref>] with particular attention to mathematics [<xref ref-type="bibr" rid="barth.REF.raches.2012.328">Raches &#x00026; Mazzocco 2012</xref>].</p>
          <p><bold>Physical therapy.</bold> The goal should be attainment of development milestones and functional outcomes while at the same time monitoring cardiovascular status [<xref ref-type="bibr" rid="barth.REF.jarvis.2001.175">Jarvis et al 2001</xref>].</p>
        </sec>
        <sec id="barth.Prevention_of_Secondary_Complicati">
          <title>Prevention of Secondary Complications</title>
          <p>Antibiotic prophylaxis has been used to prevent recurrent infections. In the French study of 22 patients, four received antibiotic prophylaxis [<xref ref-type="bibr" rid="barth.REF.rigaud.2013.70">Rigaud et al 2013</xref>].</p>
          <p>As males with Barth syndrome may be predisposed to hypoglycemia, episodes of fasting (such as prior to surgery) should be as short as possible and accompanied by intravenous glucose infusion [<xref ref-type="bibr" rid="barth.REF.schlame.2013">Schlame 2013</xref>].</p>
          <p>Potassium issues:</p>
          <list list-type="bullet">
            <list-item>
              <p>Increased risk for hypokalemia. Because males with Barth syndrome can rapidly become potassium-depleted during a gastrointestinal illness (as would anyone with marked muscular hypoplasia) [<xref ref-type="bibr" rid="barth.REF.kelley.2002">Kelley 2002</xref>], serum potassium levels should be monitored during episodes of diarrhea.</p>
            </list-item>
            <list-item>
              <p>Increased risk for hyperkalemia. Because males with Barth syndrome lack normal muscle &#x0201c;reservoir&#x0201d; for potassium, they can rapidly develop hyperkalemia when given intravenous fluids containing potassium [<xref ref-type="bibr" rid="barth.REF.kelley.2002">Kelley 2002</xref>]; thus, serum potassium levels should be monitored during the administration of intravenous fluids.</p>
            </list-item>
          </list>
          <p>Because of their growth delay, males with Barth syndrome have lower than normal caloric requirements, and attempts to induce growth by overfeeding can lead to chronic diarrhea [<xref ref-type="bibr" rid="barth.REF.kelley.2002">Kelley 2002</xref>].</p>
        </sec>
        <sec id="barth.Surveillance">
          <title>Surveillance</title>
          <p>Height and weight should be monitored on a regular basis with consideration of Barth syndrome-specific growth patterns [<xref ref-type="bibr" rid="barth.REF.roberts.2012.2726">Roberts et al 2012</xref>].</p>
          <p>Standardized cardiac evaluation including echocardiogram, ECG, and Holter monitoring should be considered at least yearly [<xref ref-type="bibr" rid="barth.REF.spencer.2005.632">Spencer et al 2005</xref>].</p>
          <p>A low threshold for performing an electrophysiologic study to assess for a potentially serious arrhythmia is appropriate, especially in the presence of symptoms such as palpitations and syncope, abnormal arrhythmia screening tests, or a family history of sudden death [<xref ref-type="bibr" rid="barth.REF.spencer.2005.632">Spencer et al 2005</xref>].</p>
        </sec>
        <sec id="barth.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Avoid the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>The use of rectal thermometers in those with neutropenia</p>
            </list-item>
            <list-item>
              <p>The use of succinylcholine, as non-depolarizing neuromuscular blockers could have a prolonged effect [<xref ref-type="bibr" rid="barth.REF.schlame.2013">Schlame 2013</xref>]</p>
            </list-item>
          </list>
          <p>The use of human growth hormone is usually discouraged, as the majority of affected males will attain normal stature by adulthood.</p>
          <p>Although the use of sevoflurane has been reported without adverse effects, the muscular involvement in Barth syndrome may increase the risk for <related-object link-type="booklink" source-id="gene" document-id="mhs" document-type="chapter">malignant hyperthermia</related-object> compared to the general population [<xref ref-type="bibr" rid="barth.REF.schlame.2013">Schlame 2013</xref>].</p>
        </sec>
        <sec id="barth.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>It is appropriate to evaluate the older and younger brothers of a proband in order to identify as early as possible those who would benefit from initiation of treatment and preventive measures.</p>
          <list list-type="bullet">
            <list-item>
              <p>If the <italic toggle="yes">TAZ</italic> pathogenic variant in the family is known, molecular genetic testing can be used to clarify the genetic status of at-risk male sibs.</p>
            </list-item>
            <list-item>
              <p>If the <italic toggle="yes">TAZ</italic> pathogenic variant in the family is not known, testing by means of MLCL:CL ratio (if available) can be used to clarify the genetic status of at-risk male sibs.</p>
            </list-item>
            <list-item>
              <p>If MLCL:CL ratio is not available, a combination of urine organic acid analysis, complete blood count with differential, and echocardiogram may be able to clarify the genetic status of at-risk male sibs. However, such testing cannot completely exclude a diagnosis of Barth syndrome.</p>
            </list-item>
          </list>
          <p>See <xref ref-type="sec" rid="barth.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="barth.Pregnancy_Management">
          <title>Pregnancy Management</title>
          <p>Given that Barth syndrome has been variably associated with different prenatal complications including intrauterine growth restriction, oligohydramnios, intrauterine ventricular dysfunction, and hydrops fetalis [<xref ref-type="bibr" rid="barth.REF.cardonick.1997.983">Cardonick et al 1997</xref>, <xref ref-type="bibr" rid="barth.REF.steward.2010.970">Steward et al 2010</xref>], it seems prudent to recommend that pregnancies of male fetuses known to have Barth syndrome be managed by a high-risk maternal fetal obstetrician. Of note, there are no specific recommendations regarding mode, timing, or location of delivery.</p>
          <p>
            <bold>Therapies Under Investigation</bold>
          </p>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p>
        </sec>
        <sec id="barth.Other">
          <title>Other</title>
          <p><bold>Pantothenic acid.</bold> The original report of successful treatment of Barth syndrome with pantothenic acid [<xref ref-type="bibr" rid="barth.REF.ostmansmith.1994.349">Ostman-Smith et al 1994</xref>] was not substantiated by later reports [<xref ref-type="bibr" rid="barth.REF.kelley.2002">Kelley 2002</xref>, <xref ref-type="bibr" rid="barth.REF.rugolotto.2003.408">Rugolotto et al 2003</xref>].</p>
          <p><bold>Coenzyme Q<sub>10</sub>.</bold> The rationale behind the use of coenzyme Q<sub>10</sub> is based on the fact that both coenzyme Q<sub>10</sub> and 3-methylglutaconic acid (3-MGC) can be produced from dimethylallyl pyrophosphate (DMAPP), an intermediate in the synthesis of cholesterol. Thus, if coenzyme Q<sub>10</sub> production is impaired, more DMAPP could potentially be shunted towards the production of 3-MGC [<xref ref-type="bibr" rid="barth.REF.costeff.1998.33">Costeff et al 1998</xref>]. However, no formal study has been undertaken to prove the efficacy of coenzyme Q<sub>10</sub> therapy in males with Barth syndrome. In a study of 15 males with Barth syndrome, three took coenzyme Q<sub>10</sub> [<xref ref-type="bibr" rid="barth.REF.spencer.2011.h2122">Spencer et al 2011</xref>].</p>
          <p><bold>Carnitine.</bold> Although early reports claimed significant benefit from carnitine supplementation in males with Barth syndrome [<xref ref-type="bibr" rid="barth.REF.ino.1988.511">Ino et al 1988</xref>], subsequent reports identified rapid deterioration in cardiac function in some cases with carnitine supplementation [<xref ref-type="bibr" rid="barth.REF.ostmansmith.1994.349">Ostman-Smith et al 1994</xref>, <xref ref-type="bibr" rid="barth.REF.kelley.2002">Kelley 2002</xref>]. Thus, unless plasma carnitine levels are low, its supplementation has no role in the treatment of Barth syndrome.</p>
          <p><bold>Arginine.</bold> Because low plasma arginine levels detected in males with Barth syndrome [<xref ref-type="bibr" rid="barth.REF.rigaud.2013.70">Rigaud et al 2013</xref>, <xref ref-type="bibr" rid="barth.REF.vernon.2014.143">Vernon et al 2014</xref>] could contribute to growth delay and cardiac abnormalities by impairing protein synthesis, it has been proposed that oral arginine supplementation be used. Improvements in ventricular function have also been noted concurrently with normalization of the amino acid profile [R Kelley, personal communication]. However, to date no formal assessments of the efficacy of this treatment have been published.</p>
        </sec>
      </sec>
      <sec id="barth.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="barth.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Barth syndrome is inherited in an X-linked manner.</p>
        </sec>
        <sec id="barth.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The father of an affected male will not have Barth syndrome nor will he be a carrier of the <italic toggle="yes">TAZ</italic> pathogenic variant.</p>
            </list-item>
            <list-item>
              <p>In a family with more than one affected individual, the mother of an affected male is an obligate carrier. Note: If a woman has more than one affected child and no other affected relatives and if the <italic toggle="yes">TAZ</italic> pathogenic variant cannot be detected in her leukocyte DNA, she has germline mosaicism. Germline mosaicism has been reported in two families with Barth syndrome [<xref ref-type="bibr" rid="barth.REF.chang.2010.198">Chang et al 2010</xref>, <xref ref-type="bibr" rid="barth.REF.momoi.2012.515">Momoi et al 2012</xref>, <xref ref-type="bibr" rid="barth.REF.rigaud.2013.70">Rigaud et al 2013</xref>].</p>
            </list-item>
            <list-item>
              <p>If a male is the only affected family member (i.e., a simplex case), the mother may be a carrier or the <italic toggle="yes">TAZ</italic> pathogenic variant in the affected male may have occurred <italic toggle="yes">de novo,</italic> and, thus, the mother is not a carrier. In the experience of one laboratory, five of 42 mothers of boys with Barth syndrome were found not to carry their son&#x02019;s pathogenic variant in their leukocyte DNA [<xref ref-type="bibr" rid="barth.REF.kirwin.2007.976.e5">Kirwin et al 2007</xref>].</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to sibs depends on the carrier status of the mother.</p>
            </list-item>
            <list-item>
              <p>If the mother of the proband has a <italic toggle="yes">TAZ</italic> pathogenic variant, the chance of transmitting it in each pregnancy is 50%. Males who inherit the <italic toggle="yes">TAZ</italic> pathogenic variant will be affected; females who inherit the <italic toggle="yes">TAZ</italic> pathogenic variant will be carriers and will not be affected.</p>
            </list-item>
            <list-item>
              <p>If the proband represents a simplex case (i.e., a single occurrence in a family) and if the <italic toggle="yes">TAZ</italic> pathogenic variant cannot be detected in the leukocyte DNA of the mother, the risk to sibs is low but greater than that of the general population because of the possibility of maternal germline mosaicism.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a male proband.</bold> Affected males pass the <italic toggle="yes">TAZ</italic> pathogenic variant to all of their daughters and none of their sons.</p>
          <p><bold>Other family members.</bold> The proband's maternal aunts may be at risk of being carriers and the aunts&#x02019; offspring, depending on their gender, may be at risk of being carriers or of being affected.</p>
          <p>Note: Molecular genetic testing may be able to identify the family member in whom the <italic toggle="yes">TAZ</italic> pathogenic variant occurred <italic toggle="yes">de novo</italic>, information that could help determine genetic risk status of the extended family. One laboratory reported that <italic toggle="yes">de novo</italic> mutation of <italic toggle="yes">TAZ</italic> occurs more frequently in a male ancestor than in a female ancestor [<xref ref-type="bibr" rid="barth.REF.kirwin.2007.976.e5">Kirwin et al 2007</xref>].</p>
        </sec>
        <sec id="barth.Carrier_Detection">
          <title>Carrier Detection</title>
          <p>Carrier testing for at-risk relatives requires prior identification of the <italic toggle="yes">TAZ</italic> pathogenic variant in the family.</p>
          <p>Note: (1) Carriers are females who are heterozygotes for this X-linked disorder and usually do not develop clinical findings related to the disorder (see Clinical Characteristics, <xref ref-type="sec" rid="barth.Clinical_Description">Clinical Description</xref>, <bold>Female heterozygotes</bold>). (2) Identification of female heterozygotes requires either (a) prior identification of the <italic toggle="yes">TAZ</italic> pathogenic variant in the family or, (b) if an affected male is not available for testing, molecular genetic testing first by sequence analysis, and then if no pathogenic variant is identified, by deletion/duplication analysis.</p>
          <p>In Barth syndrome female carriers usually demonstrate skewed X-chromosome inactivation due to preferential inactivation of the X-chromosome with the <italic toggle="yes">TAZ</italic> pathogenic variant. Thus, if the family-specific <italic toggle="yes">TAZ</italic> pathogenic variant cannot be detected or if molecular genetic testing of <italic toggle="yes">TAZ</italic> is not clinically available, X-chromosome inactivation studies may be helpful in determining if an at-risk female relative is a carrier; however, the finding of random X-chromosome inactivation does not rule out carrier status.</p>
        </sec>
        <sec id="barth.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="barth.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="barth.Prenatal_Testing_and_Preimplantati">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p>Once the <italic toggle="yes">TAZ</italic> pathogenic variant has been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic diagnosis for Barth syndrome are possible.</p>
          <p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although most centers would consider decisions about prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p>
        </sec>
      </sec>
      <sec id="barth.Resources">
        <title>Resources</title>
      </sec>
      <sec id="barth.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <p><bold>Gene structure.</bold> The longest transcript variant of <italic toggle="yes">TAZ</italic> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_000116.3">NM_000116.3</ext-link>) (previously known as G4.5, EFE2) contains 11 exons. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="barth" object-id="barth.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
        <p>Alternative splicing produces a number of different mRNAs [<xref ref-type="bibr" rid="barth.REF.bione.1996.385">Bione et al 1996</xref>, <xref ref-type="bibr" rid="barth.REF.vaz.2003.43089">Vaz et al 2003</xref>]. These include the full-length isoform (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_000116.3">NM_000116.3</ext-link>, the canonical/reference sequence), isoforms that are missing exon 5, exon 7, and both exons 5 and 7, and other less well described isoforms.</p>
        <p>The isoform missing only exon 5 (&#x00394;exon 5) was found to be functional in yeast complementation studies [<xref ref-type="bibr" rid="barth.REF.vaz.2003.43089">Vaz et al 2003</xref>]. The &#x00394;exon 5 variant is the major product of tafazzin expression in humans [<xref ref-type="bibr" rid="barth.REF.lu.2004.569">Lu et al 2004</xref>, <xref ref-type="bibr" rid="barth.REF.gonzalez.2005.409">Gonzalez 2005</xref>].</p>
        <p>Interestingly, almost 45% of the genomic sequence of <italic toggle="yes">TAZ</italic> is represented by interspersed repeated sequences (SINES and LINES) and 76% of these (accounting for 35% of the <italic toggle="yes">TAZ</italic> genomic sequence) are <italic toggle="yes">Alu</italic> sequences [<xref ref-type="bibr" rid="barth.REF.ferri.2013.27">Ferri et al 2013</xref>].</p>
        <p><xref ref-type="bibr" rid="barth.REF.ferri.2013.27">Ferri et al [2013]</xref> postulate that because of the high content of repeat sequences in this gene, <italic toggle="yes">TAZ</italic> rearrangements (which may appear to be similar in different patients on the basis of deleted exons) may actually be recurrent <italic toggle="yes">de novo</italic> pathogenic variants.</p>
        <p>Initially, when pathogenic variants in <italic toggle="yes">TAZ</italic> were implicated as the cause of Barth syndrome, it was suggested that it encoded several different proteins depending on which 5&#x02019; end and which of the differentially spliced exons were in the transcript [<xref ref-type="bibr" rid="barth.REF.bione.1996.385">Bione et al 1996</xref>]. In particular, it was thought that initiation of transcription was upstream of exons 1 and 3, leading to the hypothesis that pathogenic variants in exons 1 or 2 would produce a normal &#x0201c;short&#x0201d; mRNA and, thus, a milder phenotype. However, subsequent studies revealed only one site for initiation of transcription [<xref ref-type="bibr" rid="barth.REF.gonzalez.2005.409">Gonzalez 2005</xref>], and no significant difference in the phenotype with exon 1 or 2 pathogenic variants from that of pathogenic variants elsewhere [<xref ref-type="bibr" rid="barth.REF.spencer.2006.e337">Spencer et al 2006</xref>].</p>
        <p><bold>Normal gene product.</bold>
<italic toggle="yes">TAZ</italic> encodes tafazzin, a transacylase located on the inner mitochondrial membrane. Tafazzin catalyzes the remodeling of the acyl chains of immature cardiolipin to a mature, predominantly tetralinoleylcardiolipin. The full-length tafazzin protein contains 292 amino acids (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_000107.1">NP_000107.1</ext-link>) and has a molecular weight of 33459 daltons. It contains a transmembrane domain located at amino acids 15-35, and a phosphate acyltransferase domain at amino acids 63-217 [<xref ref-type="bibr" rid="barth.REF.uniprot_consortium.2014.d191">UniProt Consortium 2014</xref>] (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3965022/">full text</ext-link>).</p>
        <p><bold>Abnormal gene product.</bold> Cardiolipin is important for high energy-requiring tissues such as cardiac muscle; in Barth syndrome, less mature cardiolipin is produced [<xref ref-type="bibr" rid="barth.REF.schlame.2002.634">Schlame et al 2002</xref>, <xref ref-type="bibr" rid="barth.REF.valianpour.2005.1182">Valianpour et al 2005</xref>]. The exact mechanism by which decreased tetralinoleylcardiolipin leads to the pathophysiology of Barth syndrome is unclear. However, cardiolipin is involved in maintaining mitochondrial structure and organizing mitochondrial super complexes, and has an important role in apoptosis [<xref ref-type="bibr" rid="barth.REF.koshkin.2002.317">Koshkin &#x00026; Greenberg 2002</xref>, <xref ref-type="bibr" rid="barth.REF.brandner.2005.5202">Brandner et al 2005</xref>, <xref ref-type="bibr" rid="barth.REF.gonzalvez.2007.877">Gonzalvez &#x00026; Gottlieb 2007</xref>].</p>
      </sec>
      <sec id="barth.References">
        <title>References</title>
        <sec id="barth.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="barth.Literature_Cited.reflist0">
            <ref id="barth.REF.ad_s.1993.327">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ad&#x000e8;s</surname>
                    <given-names>LC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gedeon</surname>
                    <given-names>AK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilson</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Latham</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Partington</surname>
                    <given-names>MW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mulley</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nelson</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lui</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sillence</surname>
                    <given-names>DO</given-names>
                  </name>
                </person-group>
                <article-title>Barth syndrome: clinical features and confirmation of gene localisation to distal Xq28.</article-title>
                <source>Am J Med Genet.</source>
                <year>1993</year>
                <volume>45</volume>
                <fpage>327</fpage>
                <lpage>34</lpage>
                <pub-id pub-id-type="pmid">8434619</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.adwani.1997.143">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Adwani</surname>
                    <given-names>SS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Whitehead</surname>
                    <given-names>BF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rees</surname>
                    <given-names>PG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morris</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Turnball</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elliott</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Leval</surname>
                    <given-names>MR</given-names>
                  </name>
                </person-group>
                <year>1997</year>
                <article-title>Heart transplantation for Barth syndrome.</article-title>
                <source>Pediatr Cardiol</source>
                <volume>18</volume>
                <fpage>143</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">9049131</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.avery.2006">
              <mixed-citation publication-type="web">Avery R. Cornstarch. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://64.69.79.21/CMFiles/Resources/Cornstarch.pdf">online</ext-link> (pdf). 2006. Accessed 6-5-17.</mixed-citation>
            </ref>
            <ref id="barth.REF.barth.1983.327">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Barth</surname>
                    <given-names>PG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scholte</surname>
                    <given-names>HR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berden</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van der Klei-Van Moorsel</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Luyt-Houwen</surname>
                    <given-names>IE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van 't Veer-Korthof</surname>
                    <given-names>ET</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van der Harten</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sobotka-Plojhar</surname>
                    <given-names>MA</given-names>
                  </name>
                </person-group>
                <article-title>An X-linked mitochondrial disease affecting cardiac muscle, skeletal muscle and neutrophil leucocytes.</article-title>
                <source>J Neurol Sci.</source>
                <year>1983</year>
                <volume>62</volume>
                <fpage>327</fpage>
                <lpage>55</lpage>
                <pub-id pub-id-type="pmid">6142097</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.barth.1996.157">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Barth</surname>
                    <given-names>PG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van den Bogert</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bolhuis</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scholte</surname>
                    <given-names>HR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Gennip</surname>
                    <given-names>AH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schutgens</surname>
                    <given-names>RB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ketel</surname>
                    <given-names>AG</given-names>
                  </name>
                </person-group>
                <article-title>X-linked cardioskeletal myopathy and neutropenia (Barth syndrome): respiratory-chain abnormalities in cultured fibroblasts.</article-title>
                <source>J Inherit Metab Dis.</source>
                <year>1996</year>
                <volume>19</volume>
                <fpage>157</fpage>
                <lpage>60</lpage>
                <pub-id pub-id-type="pmid">8739954</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.barth.1999.273">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Barth</surname>
                    <given-names>PG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vreken</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <article-title>X-linked cardioskeletal myopathy and neutropenia (Barth syndrome) - MIM 302060.</article-title>
                <source>J Pediatr.</source>
                <year>1999</year>
                <volume>135</volume>
                <fpage>273</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">10484787</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.bione.1996.385">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bione</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>D'Adamo</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maestrini</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gedeon</surname>
                    <given-names>AK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bolhuis</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Toniolo</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <article-title>A novel X-linked gene, G4.5.(sic) is responsible for Barth syndrome.</article-title>
                <source>Nat Genet.</source>
                <year>1996</year>
                <volume>12</volume>
                <fpage>385</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">8630491</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.bleyl.1997.257">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bleyl</surname>
                    <given-names>SB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mumford</surname>
                    <given-names>BR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brown-Harrison</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pagotto</surname>
                    <given-names>LT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carey</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pysher</surname>
                    <given-names>TJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ward</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chin</surname>
                    <given-names>TK</given-names>
                  </name>
                </person-group>
                <article-title>Xq28-linked noncompaction of the left ventricular myocardium: prenatal diagnosis and pathologic analysis of affected individuals.</article-title>
                <source>Am J Med Genet.</source>
                <year>1997</year>
                <volume>72</volume>
                <fpage>257</fpage>
                <lpage>65</lpage>
                <pub-id pub-id-type="pmid">9332651</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.brady.2006.462">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Brady</surname>
                    <given-names>AN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shehata</surname>
                    <given-names>BM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fernhoff</surname>
                    <given-names>PM</given-names>
                  </name>
                </person-group>
                <article-title>X-linked fetal cardiomyopathy caused by a novel mutation in the TAZ gene.</article-title>
                <source>Prenat Diagn.</source>
                <year>2006</year>
                <volume>26</volume>
                <fpage>462</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">16548007</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.brandner.2005.5202">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Brandner</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mick</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frazier</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taylor</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meisinger</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rehling</surname>
                    <given-names>P.</given-names>
                  </name>
                </person-group>
                <article-title>Taz1, an outer mitochondrial membrane protein, affects stability and assembly of inner membrane protein complexes: implications for Barth syndrome.</article-title>
                <source>Mol Biol Cell.</source>
                <year>2005</year>
                <volume>16</volume>
                <fpage>5202</fpage>
                <lpage>14</lpage>
                <pub-id pub-id-type="pmid">16135531</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.cardonick.1997.983">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cardonick</surname>
                    <given-names>EH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kuhlman</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ganz</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pagotto</surname>
                    <given-names>LT</given-names>
                  </name>
                </person-group>
                <article-title>Prenatal clinical expression of 3-methylglutaconic aciduria: Barth syndrome.</article-title>
                <source>Prenat Diagn.</source>
                <year>1997</year>
                <volume>17</volume>
                <fpage>983</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">9358581</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.chang.2010.198">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chang</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Momoi</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shan</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mitomo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aoyagi</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Endo</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takeda</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Xing</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yu</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Watanabe</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoshida</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kanegane</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsubata</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bowles</surname>
                    <given-names>NE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ichida</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miyawaki</surname>
                    <given-names>T</given-names>
                  </name>
                  <collab>Noncompaction study collaborators</collab>
                </person-group>
                <article-title>Gonadal mosaicism of a TAZ (G4.5) mutation in a Japanese family with Barth syndrome and left ventricular noncompaction.</article-title>
                <source>Mol Genet Metab.</source>
                <year>2010</year>
                <volume>100</volume>
                <fpage>198</fpage>
                <lpage>203</lpage>
                <pub-id pub-id-type="pmid">20303308</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.chen.2002.319">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsuji</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ichida</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bowles</surname>
                    <given-names>KR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yu</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Watanabe</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hirono</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsubata</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hamamichi</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ohta</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Imai</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bowles</surname>
                    <given-names>NE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miyawaki</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Towbin</surname>
                    <given-names>JA</given-names>
                  </name>
                  <collab>Noncompaction study collaborators</collab>
                </person-group>
                <article-title>Mutation analysis of the G4.5 gene in patients with isolated left ventricular noncompaction.</article-title>
                <source>Mol Genet Metab.</source>
                <year>2002</year>
                <volume>77</volume>
                <fpage>319</fpage>
                <lpage>25</lpage>
                <pub-id pub-id-type="pmid">12468278</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.christodoulou.1994.255">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Christodoulou</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McInnes</surname>
                    <given-names>RR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jay</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilson</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Becker</surname>
                    <given-names>LE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lehotay</surname>
                    <given-names>DC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Platt</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bridge</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robinson</surname>
                    <given-names>BH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clarke</surname>
                    <given-names>JT</given-names>
                  </name>
                </person-group>
                <article-title>Barth syndrome: clinical observations and genetic linkage studies.</article-title>
                <source>Am J Med Genet.</source>
                <year>1994</year>
                <volume>50</volume>
                <fpage>255</fpage>
                <lpage>64</lpage>
                <pub-id pub-id-type="pmid">8042670</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.clarke.2013.23">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Clarke</surname>
                    <given-names>SL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bowron</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gonzalez</surname>
                    <given-names>IL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Groves</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Newbury-Ecob</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clayton</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martin</surname>
                    <given-names>RP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsai-Goodman</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garratt</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ashworth</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bowen</surname>
                    <given-names>VM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McCurdy</surname>
                    <given-names>KR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Damin</surname>
                    <given-names>MK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spencer</surname>
                    <given-names>CT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Toth</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kelley</surname>
                    <given-names>RI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steward</surname>
                    <given-names>CG</given-names>
                  </name>
                </person-group>
                <article-title>Barth syndrome.</article-title>
                <source>Orphanet J Rare Dis.</source>
                <year>2013</year>
                <volume>8</volume>
                <fpage>23</fpage>
                <pub-id pub-id-type="pmid">23398819</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.cosson.2012.115">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cosson</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Toutain</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simard</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kulik</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matyas</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guichet</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blasco</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maakaroun-Vermesse</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vaillant</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Le Caignec</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chantepie</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Labarthe</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <article-title>Barth syndrome in a female patient.</article-title>
                <source>Mol Genet Metab.</source>
                <year>2012</year>
                <volume>106</volume>
                <fpage>115</fpage>
                <lpage>20</lpage>
                <pub-id pub-id-type="pmid">22410210</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.costeff.1998.33">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Costeff</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Apter</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elpeleg</surname>
                    <given-names>ON</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prialnic</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>B&#x000f6;hles</surname>
                    <given-names>HJ</given-names>
                  </name>
                </person-group>
                <article-title>Ineffectiveness of oral coenzyme Q10 supplementation in 3-methylglutaconic aciduria, type 3.</article-title>
                <source>Brain Dev.</source>
                <year>1998</year>
                <volume>20</volume>
                <fpage>33</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">9533558</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.cox.1995.a177">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cox</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pulsipher</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rothenberg</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Korson</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kelley</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <article-title>Correction of neutropenia in Barth syndrome by G-CSF.</article-title>
                <source>Am J Hum Genet.</source>
                <year>1995</year>
                <volume>57</volume>
                <fpage>A177</fpage>
              </element-citation>
            </ref>
            <ref id="barth.REF.dale.2013">
              <mixed-citation publication-type="web">Dale DC, Bolyard AA, Marrero TM, Bonilla MA, Phan L, Steward C. Barth Syndrome and Neutropenia. Poster session. New Orleans, LA: American Society of Hematology Annual Meeting and Exposition. Abstract available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://ash.confex.com/ash/2013/webprogram/Paper61972.html">online</ext-link>. 2013. Accessed 6-5-17.</mixed-citation>
            </ref>
            <ref id="barth.REF.davey.2006.385">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Davey</surname>
                    <given-names>KM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parboosingh</surname>
                    <given-names>JS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McLeod</surname>
                    <given-names>DR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chan</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Casey</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferreira</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Snyder</surname>
                    <given-names>FF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bridge</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bernier</surname>
                    <given-names>FP</given-names>
                  </name>
                </person-group>
                <article-title>Mutation of DNAJC19, a human homologue of yeast inner mitochondrial membrane co-chaperones, causes DCMA syndrome, a novel autosomal recessive Barth syndrome-like condition.</article-title>
                <source>J Med Genet.</source>
                <year>2006</year>
                <volume>43</volume>
                <fpage>385</fpage>
                <lpage>93</lpage>
                <pub-id pub-id-type="pmid">16055927</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.donati.2006.684">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Donati</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malvagia</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pasquini</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morrone</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>La Marca</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garavaglia</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Toniolo</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zammarchi</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <article-title>Barth syndrome presenting with acute metabolic decompensation in the neonatal period.</article-title>
                <source>J Inherit Metab Dis.</source>
                <year>2006</year>
                <volume>29</volume>
                <fpage>684</fpage>
                <pub-id pub-id-type="pmid">16906470</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.elpeleg.1994.167">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Elpeleg</surname>
                    <given-names>ON</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Costeff</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Joseph</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shental</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weitz</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gibson</surname>
                    <given-names>KM</given-names>
                  </name>
                </person-group>
                <article-title>3-Methylglutaconic aciduria in the Iraqi-Jewish 'optic atrophy plus' (Costeff) syndrome.</article-title>
                <source>Dev Med Child Neurol.</source>
                <year>1994</year>
                <volume>36</volume>
                <fpage>167</fpage>
                <lpage>72</lpage>
                <pub-id pub-id-type="pmid">7510656</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.ferri.2013.27">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ferri</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Donati</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Funghini</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malvagia</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Catarzi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lugli</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ragni</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertini</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vaz</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cooper</surname>
                    <given-names>DN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guerrini</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morrone</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>New clinical and molecular insights on Barth syndrome.</article-title>
                <source>Orphanet J Rare Dis.</source>
                <year>2013</year>
                <volume>8</volume>
                <fpage>27</fpage>
                <pub-id pub-id-type="pmid">23409742</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.gedeon.1995.383">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gedeon</surname>
                    <given-names>AK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilson</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Colley</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sillence</surname>
                    <given-names>DO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mulley</surname>
                    <given-names>JC</given-names>
                  </name>
                </person-group>
                <article-title>X linked fatal infantile cardiomyopathy maps to Xq28 and is possibly allelic to Barth syndrome.</article-title>
                <source>J Med Genet.</source>
                <year>1995</year>
                <volume>32</volume>
                <fpage>383</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">7616547</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.gonzalez.2005.409">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gonzalez</surname>
                    <given-names>IL</given-names>
                  </name>
                </person-group>
                <article-title>Barth syndrome: TAZ gene mutations, mRNAs, and evolution.</article-title>
                <source>Am J Med Genet A.</source>
                <year>2005</year>
                <volume>134</volume>
                <fpage>409</fpage>
                <lpage>14</lpage>
                <pub-id pub-id-type="pmid">15793838</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.gonzalvez.2007.877">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gonzalvez</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gottlieb</surname>
                    <given-names>E.</given-names>
                  </name>
                </person-group>
                <article-title>Cardiolipin: Setting the beat of apoptosis.</article-title>
                <source>Apoptosis.</source>
                <year>2007</year>
                <volume>12</volume>
                <fpage>877</fpage>
                <lpage>85</lpage>
                <pub-id pub-id-type="pmid">17294083</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.gunayaygun.2005.1">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gunay-Aygun</surname>
                    <given-names>M.</given-names>
                  </name>
                </person-group>
                <article-title>3-Methylglutaconic aciduria: a common biochemical marker in various syndromes with diverse clinical features.</article-title>
                <source>Mol Genet Metab.</source>
                <year>2005</year>
                <volume>84</volume>
                <fpage>1</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">15719488</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.hastings.2009.185">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hastings</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steward</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsai-Goodman</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Newbury-Ecob</surname>
                    <given-names>R.</given-names>
                  </name>
                </person-group>
                <article-title>Dysmorphology of Barth syndrome.</article-title>
                <source>Clin Dysmorphol.</source>
                <year>2009</year>
                <volume>18</volume>
                <fpage>185</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">19648820</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.houtkooper.2009.230">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Houtkooper</surname>
                    <given-names>RH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodenburg</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thiels</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Lenthe</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stet</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poll-The</surname>
                    <given-names>BT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stone</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steward</surname>
                    <given-names>CG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smeitink</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kulik</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vaz</surname>
                    <given-names>FM</given-names>
                  </name>
                </person-group>
                <article-title>Cardiolipin and monolysocardiolipin analysis in fibroblasts, lymphocytes, and tissues using high-performance liquid chromatography-mass spectrometry as a diagnostic test for Barth syndrome.</article-title>
                <source>Anal Biochem.</source>
                <year>2009</year>
                <volume>387</volume>
                <fpage>230</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">19454236</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.ichida.2001.1256">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ichida</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsubata</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bowles</surname>
                    <given-names>KR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haneda</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Uese</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miyawaki</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dreyer</surname>
                    <given-names>WJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Messina</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bowles</surname>
                    <given-names>NE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Towbin</surname>
                    <given-names>JA</given-names>
                  </name>
                </person-group>
                <article-title>Novel gene mutations in patients with left ventricular noncompaction or Barth syndrome.</article-title>
                <source>Circulation.</source>
                <year>2001</year>
                <volume>103</volume>
                <fpage>1256</fpage>
                <lpage>63</lpage>
                <pub-id pub-id-type="pmid">11238270</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.ino.1988.511">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ino</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sherwood</surname>
                    <given-names>WG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cutz</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Benson</surname>
                    <given-names>LN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rose</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Freedom</surname>
                    <given-names>RM</given-names>
                  </name>
                </person-group>
                <article-title>Dilated cardiomyopathy with neutropenia, short stature, and abnormal carnitine metabolism.</article-title>
                <source>J Pediatr.</source>
                <year>1988</year>
                <volume>113</volume>
                <fpage>511</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">3411399</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.jarvis.2001.175">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jarvis</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garrett</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Svien</surname>
                    <given-names>L</given-names>
                  </name>
                </person-group>
                <article-title>Gross motor development of a toddler with Barth syndrome, an x-linked recessive disorder: a case report.</article-title>
                <source>Pediatr Phys Ther.</source>
                <year>2001</year>
                <volume>13</volume>
                <fpage>175</fpage>
                <lpage>81</lpage>
                <pub-id pub-id-type="pmid">17053636</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.johnston.1997.1053">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Johnston</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kelley</surname>
                    <given-names>RI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feigenbaum</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cox</surname>
                    <given-names>GF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iyer</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Funanage</surname>
                    <given-names>VL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Proujansky</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <article-title>Mutation characterization and genotype-phenotype correlation in Barth syndrome.</article-title>
                <source>Am J Hum Genet.</source>
                <year>1997</year>
                <volume>61</volume>
                <fpage>1053</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">9345098</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.kelley.2002">
              <mixed-citation publication-type="book">Kelley RI. Barth Syndrome - X-linked Cardiomyopathy and Neutropenia. Johns Hopkins Medicine. 2002.</mixed-citation>
            </ref>
            <ref id="barth.REF.kelley.1991.738">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kelley</surname>
                    <given-names>RI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cheatham</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clark</surname>
                    <given-names>BJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nigro</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Powell</surname>
                    <given-names>BR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sherwood</surname>
                    <given-names>GW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sladky</surname>
                    <given-names>JT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Swisher</surname>
                    <given-names>WP</given-names>
                  </name>
                </person-group>
                <article-title>X-linked dilated cardiomyopathy with neutropenia, growth retardation, and 3-methylglutaconic aciduria.</article-title>
                <source>J Pediatr.</source>
                <year>1991</year>
                <volume>119</volume>
                <fpage>738</fpage>
                <lpage>47</lpage>
                <pub-id pub-id-type="pmid">1719174</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.kenton.2004.162">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kenton</surname>
                    <given-names>AB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sanchez</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coveler</surname>
                    <given-names>KJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Makar</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jimenez</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ichida</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murphy</surname>
                    <given-names>RT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elliott</surname>
                    <given-names>PM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McKenna</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bowles</surname>
                    <given-names>NE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Towbin</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bowles</surname>
                    <given-names>KR</given-names>
                  </name>
                </person-group>
                <article-title>Isolated left ventricular noncompaction is rarely caused by mutations in G4.5, alpha-dystrobrevin and FK Binding Protein-12.</article-title>
                <source>Mol Genet Metab.</source>
                <year>2004</year>
                <volume>82</volume>
                <fpage>162</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">15172004</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.kirwin.2007.976.e5">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kirwin</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vinette</surname>
                    <given-names>KM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwartz</surname>
                    <given-names>SB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Funanage</surname>
                    <given-names>VL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gonzalez</surname>
                    <given-names>IL</given-names>
                  </name>
                </person-group>
                <article-title>Multiple transmissions of Barth syndrome through an oocyte donor with a de novo TAZ mutation.</article-title>
                <source>Fertil Steril.</source>
                <year>2007</year>
                <volume>87</volume>
                <fpage>976.e5</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">17241629</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.klein.2011.399">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Klein</surname>
                    <given-names>C.</given-names>
                  </name>
                </person-group>
                <article-title>Genetic defects in severe congenital neutropenia: emerging insights into life and death of human neutrophil granulocytes.</article-title>
                <source>Annu Rev Immunol.</source>
                <year>2011</year>
                <volume>29</volume>
                <fpage>399</fpage>
                <lpage>413</lpage>
                <pub-id pub-id-type="pmid">21219176</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.klein.2007.86">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Klein</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grudzien</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Appaswamy</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Germeshausen</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sandrock</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sch&#x000e4;ffer</surname>
                    <given-names>AA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rathinam</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boztug</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwinzer</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rezaei</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bohn</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Melin</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carlsson</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fadeel</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dahl</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Palmblad</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Henter</surname>
                    <given-names>JI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeidler</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grimbacher</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Welte</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <article-title>HAX1 deficiency causes autosomal recessive severe congenital neutropenia (Kostmann disease).</article-title>
                <source>Nat Genet.</source>
                <year>2007</year>
                <volume>39</volume>
                <fpage>86</fpage>
                <lpage>92</lpage>
                <pub-id pub-id-type="pmid">17187068</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.koshkin.2002.317">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Koshkin</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Greenberg</surname>
                    <given-names>ML</given-names>
                  </name>
                </person-group>
                <article-title>Cardiolipin prevents rate-dependent uncoupling and provides osmotic stability in yeast mitochondria.</article-title>
                <source>Biochem J.</source>
                <year>2002</year>
                <volume>364</volume>
                <fpage>317</fpage>
                <lpage>22</lpage>
                <pub-id pub-id-type="pmid">11988106</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.kulik.2008.371">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kulik</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Lenthe</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stet</surname>
                    <given-names>FS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Germeshausen</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sandrock</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sch&#x000e4;ffer</surname>
                    <given-names>AA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rathinam</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boztug</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwinzer</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rezaei</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bohn</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Melin</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carlsson</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fadeel</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dahl</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Palmblad</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Henter</surname>
                    <given-names>JI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeidler</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grimbacher</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Welte</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <article-title>Bloodspot assay using HPLC-tandem mass spectrometry for detection of Barth syndrome.</article-title>
                <source>Clin Chem.</source>
                <year>2008</year>
                <volume>54</volume>
                <fpage>371</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">18070816</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.lu.2004.569">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lu</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kelher</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>DP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lewin</surname>
                    <given-names>TM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coleman</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Choy</surname>
                    <given-names>PC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hatch</surname>
                    <given-names>GM</given-names>
                  </name>
                </person-group>
                <article-title>Complex expression pattern of the Barth syndrome gene product tafazzin in human cell lines and murine tissues.</article-title>
                <source>Biochem Cell Biol.</source>
                <year>2004</year>
                <volume>82</volume>
                <fpage>569</fpage>
                <lpage>76</lpage>
                <pub-id pub-id-type="pmid">15499385</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.mangat.2007.327">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mangat</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lunnon-Wood</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rees</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elliot</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burch</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Successful cardiac transplantation in Barth syndrome--single-centre experience of four patients.</article-title>
                <source>Pediatr Transplant.</source>
                <year>2007</year>
                <volume>11</volume>
                <fpage>327</fpage>
                <lpage>31</lpage>
                <pub-id pub-id-type="pmid">17430492</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.mazzocco.2007.22">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mazzocco</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Henry</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kelly</surname>
                    <given-names>RI</given-names>
                  </name>
                </person-group>
                <article-title>Barth syndrome is associated with a cognitive phenotype.</article-title>
                <source>J Dev Behav Pediatr.</source>
                <year>2007</year>
                <volume>28</volume>
                <fpage>22</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">17353728</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.momoi.2012.515">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Momoi</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chang</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takeda</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aoyagi</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Endo</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ichida</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <article-title>Differing clinical courses and outcomes in two siblings with Barth syndrome and left ventricular noncompaction.</article-title>
                <source>Eur J Pediatr.</source>
                <year>2012</year>
                <volume>171</volume>
                <fpage>515</fpage>
                <lpage>20</lpage>
                <pub-id pub-id-type="pmid">21987083</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.orstavik.1998.1457">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Orstavik</surname>
                    <given-names>KH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Orstavik</surname>
                    <given-names>RE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Naumova</surname>
                    <given-names>AK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>D'Adamo</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gedeon</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bolhuis</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barth</surname>
                    <given-names>PG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Toniolo</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <article-title>X chromosome inactivation in carriers of Barth syndrome.</article-title>
                <source>Am J Hum Genet.</source>
                <year>1998</year>
                <volume>63</volume>
                <fpage>1457</fpage>
                <lpage>63</lpage>
                <pub-id pub-id-type="pmid">9792874</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.ostmansmith.1994.349">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ostman-Smith</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brown</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Johnson</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Land</surname>
                    <given-names>JM</given-names>
                  </name>
                </person-group>
                <article-title>Dilated cardiomyopathy due to type II X-linked 3-methylglutaconic aciduria: successful treatment with pantothenic acid.</article-title>
                <source>Br Heart J.</source>
                <year>1994</year>
                <volume>72</volume>
                <fpage>349</fpage>
                <lpage>53</lpage>
                <pub-id pub-id-type="pmid">7833193</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.raches.2012.328">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Raches</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mazzocco</surname>
                    <given-names>MM</given-names>
                  </name>
                </person-group>
                <article-title>Emergence and nature of mathematical difficulties in young children with Barth syndrome.</article-title>
                <source>J Dev Behav Pediatr.</source>
                <year>2012</year>
                <volume>33</volume>
                <fpage>328</fpage>
                <lpage>35</lpage>
                <pub-id pub-id-type="pmid">22566029</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.reynolds.2012.1647">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Reynolds</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kreider</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bendixen</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <article-title>A mixed-methods investigation of sensory response patterns in Barth syndrome: a clinical phenotype?</article-title>
                <source>Am J Med Genet A.</source>
                <year>2012</year>
                <volume>158A</volume>
                <fpage>1647</fpage>
                <lpage>53</lpage>
                <pub-id pub-id-type="pmid">22711649</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.rigaud.2013.70">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rigaud</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lebre</surname>
                    <given-names>A-S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Touraine</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beaupain</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ottolenghi</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chabli</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ansquer</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ozsahin</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Di Filippo</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Lonlay</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Borm</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rivier</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vaillant</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mathieu-Dramard</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goldenberg</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Viot</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Charron</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rio</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonnet</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Donadieu</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>Natural history of Barth syndrome: a national cohort study of 22 patients.</article-title>
                <source>Orphanet J Rare Dis.</source>
                <year>2013</year>
                <volume>8</volume>
                <fpage>70</fpage>
                <pub-id pub-id-type="pmid">23656970</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.roberts.2012.2726">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Roberts</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nixon</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steward</surname>
                    <given-names>CG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gauvreau</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maisenbacher</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fletcher</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Geva</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Byrne</surname>
                    <given-names>BJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spencer</surname>
                    <given-names>CT</given-names>
                  </name>
                </person-group>
                <article-title>The Barth Syndrome Registry: distinguishing disease characteristics and growth data from a longitudinal study.</article-title>
                <source>Am J Med Genet A.</source>
                <year>2012</year>
                <volume>158A</volume>
                <fpage>2726</fpage>
                <lpage>32</lpage>
                <pub-id pub-id-type="pmid">23045169</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.ronvelia.2012.428">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ronvelia</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Greenwood</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Platt</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hakim</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zaragoza</surname>
                    <given-names>MV</given-names>
                  </name>
                </person-group>
                <article-title>Intrafamilial variability for novel TAZ gene mutation: Barth syndrome with dilated cardiomyopathy and heart failure in an infant and left ventricular noncompaction in his great-uncle.</article-title>
                <source>Mol Genet Metab.</source>
                <year>2012</year>
                <volume>107</volume>
                <fpage>428</fpage>
                <lpage>32</lpage>
                <pub-id pub-id-type="pmid">23031367</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.rugolotto.2003.408">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rugolotto</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prioli</surname>
                    <given-names>MD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Toniolo</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pellegrino</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Catuogno</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burlina</surname>
                    <given-names>AB</given-names>
                  </name>
                </person-group>
                <article-title>Long-term treatment of Barth syndrome with pantothenic acid: a retrospective study.</article-title>
                <source>Mol Genet Metab.</source>
                <year>2003</year>
                <volume>80</volume>
                <fpage>408</fpage>
                <lpage>11</lpage>
                <pub-id pub-id-type="pmid">14654353</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.schlame.2013">
              <mixed-citation publication-type="web">Schlame M. Information for anaesthesiologists and surgeons taking care of patients with Barth syndrome. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://64.69.79.21/CMFiles/Resources/AnaesthesiologistsSurgeonsInformationBTHSSchlame.pdf">online</ext-link> (pdf). 2013. Accessed 6-5-17.</mixed-citation>
            </ref>
            <ref id="barth.REF.schlame.2002.634">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Schlame</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Towbin</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heerdt</surname>
                    <given-names>PM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jehle</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DiMauro</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blanck</surname>
                    <given-names>TJ</given-names>
                  </name>
                </person-group>
                <article-title>Deficiency of tetralinoleoyl-cardiolipin in Barth syndrome.</article-title>
                <source>Ann Neurol.</source>
                <year>2002</year>
                <volume>51</volume>
                <fpage>634</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">12112112</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.schmidt.2004.419">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Schmidt</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Birkebaek</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gonzalez</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sunde</surname>
                    <given-names>L</given-names>
                  </name>
                </person-group>
                <article-title>Barth syndrome without 3-methylglutaconic aciduria.</article-title>
                <source>Acta Paediatr.</source>
                <year>2004</year>
                <volume>93</volume>
                <fpage>419</fpage>
                <lpage>21</lpage>
                <pub-id pub-id-type="pmid">15124852</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.spencer.2005.632">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Spencer</surname>
                    <given-names>CT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Byrne</surname>
                    <given-names>BJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gewitz</surname>
                    <given-names>MH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wechsler</surname>
                    <given-names>SB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kao</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gerstenfeld</surname>
                    <given-names>EP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Merliss</surname>
                    <given-names>AD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carboni</surname>
                    <given-names>MP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bryant</surname>
                    <given-names>RM</given-names>
                  </name>
                </person-group>
                <article-title>Ventricular arrhythmia in the X-linked cardiomyopathy Barth syndrome.</article-title>
                <source>Pediatr Cardiol.</source>
                <year>2005</year>
                <volume>26</volume>
                <fpage>632</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">16235007</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.spencer.2006.e337">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Spencer</surname>
                    <given-names>CT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bryant</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Day</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gonzalez</surname>
                    <given-names>IL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Colan</surname>
                    <given-names>SD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thompson</surname>
                    <given-names>WR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berthy</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Redfearn</surname>
                    <given-names>SP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Byrne</surname>
                    <given-names>BJ</given-names>
                  </name>
                </person-group>
                <article-title>Cardiac and clinical phenotype in Barth syndrome.</article-title>
                <source>Pediatrics.</source>
                <year>2006</year>
                <volume>118</volume>
                <fpage>e337</fpage>
                <lpage>46</lpage>
                <pub-id pub-id-type="pmid">16847078</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.spencer.2011.h2122">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Spencer</surname>
                    <given-names>CT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Byrne</surname>
                    <given-names>BJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bryant</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Margossian</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maisenbacher</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Breitenger</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Benni</surname>
                    <given-names>PB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Redfearn</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marcus</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cade</surname>
                    <given-names>WT</given-names>
                  </name>
                </person-group>
                <article-title>Impaired cardiac reserve and severely diminished skeletal muscle O2 utilization mediate exercise intolerance in Barth syndrome.</article-title>
                <source>Am J Physiol Heart Circ Physiol.</source>
                <year>2011</year>
                <volume>301</volume>
                <fpage>H2122</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">21873497</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.statile.2013.67">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Statile</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taylor</surname>
                    <given-names>MD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mazur</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cripe</surname>
                    <given-names>LH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>King</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pratt</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Benson</surname>
                    <given-names>DW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hor</surname>
                    <given-names>KN</given-names>
                  </name>
                </person-group>
                <article-title>Left ventricular noncompaction in Duchenne muscular dystrophy.</article-title>
                <source>J Cardiovasc Magn Reson.</source>
                <year>2013</year>
                <volume>15</volume>
                <fpage>67</fpage>
                <pub-id pub-id-type="pmid">23914774</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.stenson.2003.577">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Stenson</surname>
                    <given-names>PD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ball</surname>
                    <given-names>EV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mort</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Phillips</surname>
                    <given-names>AD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shiel</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thomas</surname>
                    <given-names>NS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abeysinghe</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krawczak</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cooper</surname>
                    <given-names>DN</given-names>
                  </name>
                </person-group>
                <article-title>Human Gene Mutation Database (HGMD): 2003 update.</article-title>
                <source>Hum Mutat.</source>
                <year>2003</year>
                <volume>21</volume>
                <fpage>577</fpage>
                <lpage>81</lpage>
                <pub-id pub-id-type="pmid">12754702</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.steward.2010.970">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Steward</surname>
                    <given-names>CG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Newbury-Ecob</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hastings</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smithson</surname>
                    <given-names>SF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsai-Goodman</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quarrell</surname>
                    <given-names>OW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kulik</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pennock</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Williams</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cresswell</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gonzalez</surname>
                    <given-names>IL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brennan</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <article-title>Barth syndrome: an X-linked cause of fetal cardiomyopathy and stillbirth.</article-title>
                <source>Prenat Diagn.</source>
                <year>2010</year>
                <volume>30</volume>
                <fpage>970</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">20812380</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.storch.2009.137">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Storch</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Keeley</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Merlo</surname>
                    <given-names>LJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>St Amant</surname>
                    <given-names>JB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jacob</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Storch</surname>
                    <given-names>JF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spencer</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Byrne</surname>
                    <given-names>BJ</given-names>
                  </name>
                </person-group>
                <article-title>Psychosocial functioning in youth with Barth syndrome.</article-title>
                <source>Child Health Care.</source>
                <year>2009</year>
                <volume>38</volume>
                <fpage>137</fpage>
                <lpage>56</lpage>
                <pub-id pub-id-type="pmid">20808735</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.sweetman.2001">
              <mixed-citation publication-type="book">Sweetman L, Williams JC. Branched chain organic acidurias. In: Scriver C, Beaudet A, Sly W, Valle D, eds. <italic toggle="yes">The Metabolic Basis of Inherited Disease</italic>. 8 ed. New York, NY: McGraw-Hill; 2001:2125-63.</mixed-citation>
            </ref>
            <ref id="barth.REF.takeda.2011.1481">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Takeda</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sudo</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamada</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamazawa</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Izumi</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nishino</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ariga</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <article-title>Barth syndrome diagnosed in the subclinical stage of heart failure based on the presence of lipid storage myopathy and isolated noncompaction of the ventricular myocardium.</article-title>
                <source>Eur J Pediatr.</source>
                <year>2011</year>
                <volume>170</volume>
                <fpage>1481</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">21932011</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.uniprot_consortium.2014.d191">
              <element-citation publication-type="journal">
                <person-group>
                  <collab>UniProt Consortium</collab>
                </person-group>
                <article-title>Activities at the Universal Protein Resource (UniProt).</article-title>
                <source>Nucleic Acids Res.</source>
                <year>2014</year>
                <volume>42</volume>
                <fpage>D191</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">24253303</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.valianpour.2005.1182">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Valianpour</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mitsakos</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schlemmer</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Towbin</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taylor</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ekert</surname>
                    <given-names>PG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thorburn</surname>
                    <given-names>DR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Munnich</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barth</surname>
                    <given-names>PG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vaz</surname>
                    <given-names>FM</given-names>
                  </name>
                </person-group>
                <article-title>Monolysocardiolipins accumulate in Barth syndrome but do not lead to enhanced apoptosis.</article-title>
                <source>J Lipid Res.</source>
                <year>2005</year>
                <volume>46</volume>
                <fpage>1182</fpage>
                <lpage>95</lpage>
                <pub-id pub-id-type="pmid">15805542</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.van_werkhoven.2006.2346">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>van Werkhoven</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thorburn</surname>
                    <given-names>DR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gedeon</surname>
                    <given-names>AK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pitt</surname>
                    <given-names>JJ</given-names>
                  </name>
                </person-group>
                <article-title>Monolysocardiolipin in cultured fibroblasts is a sensitive and specific marker for Barth Syndrome.</article-title>
                <source>J Lipid Res.</source>
                <year>2006</year>
                <volume>47</volume>
                <fpage>2346</fpage>
                <lpage>51</lpage>
                <pub-id pub-id-type="pmid">16873891</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.vaz.2003.43089">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Vaz</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Houtkooper</surname>
                    <given-names>RH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valianpour</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barth</surname>
                    <given-names>PG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <article-title>Only one splice variant of the human TAZ gene encodes a functional protein with a role in cardiolipin metabolism.</article-title>
                <source>J Biol Chem.</source>
                <year>2003</year>
                <volume>278</volume>
                <fpage>43089</fpage>
                <lpage>94</lpage>
                <pub-id pub-id-type="pmid">12930833</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.vernon.2013">
              <mixed-citation publication-type="web">Vernon H, McClellan R, Cordova A, Kelley RI, Sandlers Y. Biochemical and hematologic laboratory studies in a cohort of patients with Barth syndrome. Boston, MA: American Society of Human Genetics Annual Meeting. Abstract available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ashg.org/2013meeting/abstracts/fulltext/f130120377.htm">online</ext-link>. 2013. Accessed 6-5-17.</mixed-citation>
            </ref>
            <ref id="barth.REF.vernon.2014.143">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Vernon</surname>
                    <given-names>HJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sandlers</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McClellan</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kelley</surname>
                    <given-names>RI</given-names>
                  </name>
                </person-group>
                <article-title>Clinical laboratory studies in Barth Syndrome.</article-title>
                <source>Mol Genet Metab.</source>
                <year>2014</year>
                <volume>112</volume>
                <fpage>143</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">24751896</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.wortmann.2013.923">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wortmann</surname>
                    <given-names>SB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duran</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anikster</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barth</surname>
                    <given-names>PG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sperl</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zschocke</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morava</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wevers</surname>
                    <given-names>RA</given-names>
                  </name>
                </person-group>
                <article-title>Inborn errors of metabolism with 3-methylglutaconic aciduria as discriminative feature: proper classification and nomenclature.</article-title>
                <source>J Inherit Metab Dis.</source>
                <year>2013</year>
                <volume>36</volume>
                <fpage>923</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">23296368</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.wortmann.2015.99">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wortmann</surname>
                    <given-names>SB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Espeel</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Almeida</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reimer</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bosboom</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roels</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Brouwer</surname>
                    <given-names>AP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wevers</surname>
                    <given-names>RA</given-names>
                  </name>
                </person-group>
                <article-title>Inborn errors of metabolism in the biosynthesis and remodelling of phospholipids.</article-title>
                <source>J Inherit Metab Dis.</source>
                <year>2015</year>
                <volume>38</volume>
                <fpage>99</fpage>
                <lpage>110</lpage>
                <pub-id pub-id-type="pmid">25178427</pub-id>
              </element-citation>
            </ref>
            <ref id="barth.REF.yen.2008.941">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yen</surname>
                    <given-names>TY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hwu</surname>
                    <given-names>W-L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chien</surname>
                    <given-names>Y-H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wu</surname>
                    <given-names>MH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lin</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsao</surname>
                    <given-names>LY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hsieh</surname>
                    <given-names>WS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>NC</given-names>
                  </name>
                </person-group>
                <article-title>Acute metabolic decompensation and sudden death in Barth syndrome: report of a family and a literature review.</article-title>
                <source>Eur J Pediatr.</source>
                <year>2008</year>
                <volume>167</volume>
                <fpage>941</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">17846786</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="barth.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="barth.Acknowledgments">
          <title>Acknowledgments</title>
          <p>We would like to acknowledge the Barth Syndrome Foundation for their support.</p>
        </sec>
        <sec id="barth.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>9 October 2014 (me) Review posted live</p>
            </list-item>
            <list-item>
              <p>7 April 2014 (cf) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
